U.S. patent application number 14/711156 was filed with the patent office on 2016-01-07 for cyclopropylamine inhibitors of oxidases.
The applicant listed for this patent is Oryzon Genomics S.A.. Invention is credited to Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Alberto Ortega Munoz, N ria Valls Vidal.
Application Number | 20160000768 14/711156 |
Document ID | / |
Family ID | 45390061 |
Filed Date | 2016-01-07 |
United States Patent
Application |
20160000768 |
Kind Code |
A1 |
Castro-Palomino Laria; Julio ;
et al. |
January 7, 2016 |
CYCLOPROPYLAMINE INHIBITORS OF OXIDASES
Abstract
The invention relates to cyclopropylamine compounds, in
particular the compounds of Formula (I) as described and defined
herein, and their use in therapy, including, e.g., the treatment or
prevention of cancer. ##STR00001##
Inventors: |
Castro-Palomino Laria; Julio;
(Premia de Mar, ES) ; Fyfe; Matthew Colin Thor;
(Chipping Norton, GB) ; Martinell Pedemonte; Marc;
(Barcelona, ES) ; Ortega Munoz; Alberto;
(Barcelona, ES) ; Valls Vidal; N ria; (Barcelona,
ES) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Oryzon Genomics S.A. |
Cornella de Llobregat |
|
ES |
|
|
Family ID: |
45390061 |
Appl. No.: |
14/711156 |
Filed: |
May 13, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13877919 |
Jul 15, 2013 |
9061966 |
|
|
PCT/EP2011/067608 |
Oct 7, 2011 |
|
|
|
14711156 |
|
|
|
|
Current U.S.
Class: |
514/338 ;
514/339; 514/352; 514/524; 514/619; 514/646; 514/658 |
Current CPC
Class: |
A61K 31/277 20130101;
C07C 237/30 20130101; A61P 31/12 20180101; C07C 255/58 20130101;
A61K 31/166 20130101; C07D 401/12 20130101; A61P 35/00 20180101;
C07C 211/56 20130101; A61K 31/136 20130101; A61K 31/4418 20130101;
C07C 211/55 20130101; A61K 31/4439 20130101; C07C 211/53 20130101;
C07C 211/52 20130101; C07D 213/74 20130101; A61P 25/00 20180101;
C07C 217/92 20130101 |
International
Class: |
A61K 31/4439 20060101
A61K031/4439; A61K 31/166 20060101 A61K031/166; A61K 31/277
20060101 A61K031/277; A61K 31/4418 20060101 A61K031/4418; A61K
31/136 20060101 A61K031/136 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 8, 2010 |
EP |
10187039.2 |
Claims
1-27. (canceled)
28. A method of treating or preventing cancer, a neurological
disease or condition, a viral infection, or reactivation of a virus
after latency, the method comprising administering, to a subject in
need of such treatment or prevention, a compound of formula (I):
##STR00050## wherein: E is --X.sup.3.dbd.X.sup.4--, --N(R3)-,
--S--, or --O--; X.sup.1 and X.sup.2 are each independently C(R2)
or N; X.sup.3 and X.sup.4, when present, are each independently
C(R2) or N; L1 is --NH-- or --NH--CH.sub.2--; G is a cyclyl group;
each R1 is independently chosen from alkyl, alkenyl, alkynyl,
cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido, nitro,
halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, and carboxyl;
each R2 is independently chosen from --H, alkyl, alkenyl, alkynyl,
cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl amino, amido, nitro,
halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, and carboxyl,
wherein each R2 group has 1, 2, or 3 independently chosen optional
substituents, and further wherein two R2 groups bound to adjacent
carbon atoms can be taken together to form a heterocyclyl or aryl
group having 1, 2, or 3 independently chosen optional substituents;
wherein said optional substituents are each independently chosen
from alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl
cycloalkyl, carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl,
aryloxy, heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy,
carbonyl, carboxyl, carboxamido, cyano, halogen, hydroxyl, amino,
aminoalkyl, amidoalkyl, amido, nitro, thiol, alkylthio, arylthio,
sulfinyl, sulfonyl, sulfonamide, urea and carbamate; R3 is --H or
an (C1-C6)alkyl group; each L2 is independently chosen from
alkylene and heteroalkylene; and n is 0, 1, 2, 3, 4 or 5; or a
pharmaceutically acceptable salt or solvate thereof.
29. The method of claim 28, wherein said cancer is chosen from
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia and lymphoma.
30-31. (canceled)
32. The method of claim 28, wherein said neurological disease or
condition is chosen from depression, Alzheimer's disease,
Huntington disease, Parkinson's disease, and or Dementia with Lewy
Bodies.
33. (canceled)
34. A method of modulating histone methylation levels in a
mammalian cell, the method comprising administering a compound of
formula (I): ##STR00051## wherein: E is --X.sup.3.dbd.X.sup.4--,
--N(R3)-, --S--, or --O--; X.sup.1 and X.sup.2 are each
independently C(R2) or N; X.sup.3 and X.sup.4, when present, are
each independently C(R2) or N; L1 is --NH-- or --NH--CH--; G is a
cyclyl group; each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, and carboxyl;
each R2 is independently chosen from --H, alkyl, alkenyl, alkynyl,
cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido, nitro,
halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, and carboxyl,
wherein each R2 group has 1, 2, or 3 independently chosen optional
substituents, and further wherein two R2 groups bound to adjacent
carbon atoms can be taken together to form a heterocyclyl or aryl
group having 1, 2, or 3 independently chosen optional substituents;
wherein said optional substituents are each independently chosen
from alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl,
cycloalkyl, carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl,
aryloxy, heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy,
carbonyl, carboxyl, carboxamido, cyano, halogen, hydroxyl, amino,
aminoalkyl, amidoalkyl, amido, nitro, thiol, alkylthio, arylthio,
sulfinyl, sulfonyl, sulfonamide, urea and carbamate; R3 is --H or
an (C1-C6)alkyl group; each L2 is independently chosen from
alkylene and heteroalkylene; and n is 0, 1, 2, 3, 4 or 5; or a
pharmaceutically acceptable salt or solvate thereof.
35. The method of claim 34, wherein histone-3 lysine-4 methylation
levels are modulated.
36. The method of claim 34, wherein histone-3 lysine-9 methylation
levels are modulated.
37. A method of modulating gene expression levels in a mammalian
cell, the method comprising administering a compound of formula
(I): ##STR00052## wherein: E is --X.sup.3.dbd.X.sup.4--, --N(R3)-,
--S-- or --O--; X.sup.1 and X.sup.2 are each independently C(R2) or
N; X.sup.3 and X.sup.4, when present, are each independently C(R2)
or N; L1 is --NH-- or --NH--CH.sub.2--; G is a cyclyl group; each
R1 is independently chosen from alkyl, alkenyl, alkynyl, cyclyl,
-L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido, nitro, halo,
haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl, sulfonamide,
hydroxyl, alkoxy, urea, carbamate, acyl, and carboxyl; each R2 is
independently chosen from --H, alkyl, alkenyl, alkynyl, cyclyl,
-L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido, nitro, halo,
haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl, sulfonamide,
hydroxyl, alkoxy, urea, carbamate, acyl, and carboxyl, wherein each
R2 group has 1, 2, or 3 independently chosen optional substituents,
and further wherein two R2 groups bound to adjacent carbon atoms
can be taken together to form a heterocycyl or aryl group having 1,
2, or 3 independently chosen optional substituents; wherein said
optional substituents are each independently chosen from alkyl,
alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea and carbamate; R3 is --H or an
(C1-C6)alkyl group; each L2 is independently chosen from alkylene
and heteroalkylene; and n is 0, 1, 2, 3, 4 or 5; or a
pharmaceutically acceptable salt or solvate thereof.
38-46. (canceled)
47. The method of claim 28, wherein said subject is a human.
48. The method of claim 28, wherein L1 is --NH--.
49. The method of claim 28, wherein L1 is --NH--CH.sub.s--.
50. The method of claim 28, wherein G is aryl or heterocyclyl.
51. The method of claim 28, wherein G is aryl or heteroaryl.
52. The method of claim 28, wherein G is heterocyclyl.
53. The method of claim 28, wherein E is
--X.sup.3.dbd.X.sup.4--.
54. The method of claim 53, wherein one of X.sup.1, X.sup.2,
X.sup.3, and X.sup.4 is N or C(R2) and the other ones of X.sup.1,
X.sup.2, X.sup.3, and X.sup.4 are each independently C(R2).
55. The method of claim 53, wherein one of X.sup.1, X.sup.2,
X.sup.3 and X.sup.4 is N and the other ones of X.sup.1, X.sup.2,
X.sup.3 and X.sup.4 are each independently C(R2).
56. The method of claim 28, wherein each R1 is independently chosen
from lower alkyl, lower alkynyl, amido, halo, lower haloalkyl,
cyano, hydroxyl, and alkoxy.
57. The method of claim 28, wherein each R2 is --H.
58. The method of claim 28, wherein the compound of Formula (I) is
in the trans configuration in respect of the substituents on the
cyclopropyl ring.
59. The method of claim 28, wherein the compound of formula (I) is
chosen from:
5-((trans)-2-aminocyclopropyl)-N-(3-chlorophenyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)phenyl)pyridin-2-ami-
ne;
5-((trans)-2-aminocyclopropyl)-N-(3-methoxyphenyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-(4-methoxyphenyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-p-tolylpyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-m-tolylpyridin-2-amine;
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile;
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile;
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide;
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide;
5-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-(4-chlorobenzyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-(3-(trifluoromethyl)benzyl)pyridin-2-ami-
ne;
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)benzyl)pyridin-2--
amine;
5-((trans)-2-aminocyclopropyl)-N-(3-methylbenzyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-(4-methylbenzyl)pyridin-2-amine;
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzonitrile;
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzonitrile;
5-((trans)-2-aminocyclopropyl)-N-(3-methoxybenzyl)pyridin-2-amine;
5-((trans)-2-aminocyclopropyl)-N-(4-methoxybenzyl)pyridin-2-amine;
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol;
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzamide;
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzamide;
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)phenol;
5-((trans)-2-aminocyclopropyl)-N-(3-ethynylphenyl)pyridin-2-amine;
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indol-7-amine;
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indazol-7-amine;
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol;
4-((trans)-2-aminocyclopropyl)-N-(4-methylbenzyl)aniline;
4-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)benzyl)aniline;
4-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)aniline;
3-(((4-((trans)-2-aminocyclopropyl)phenyl)amino)methyl)benzonitrile;
4-((trans)-2-aminocyclopropyl)-N-(p-tolyl)aniline;
4-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)aniline;
3-((4-((trans)-2-aminocyclopropyl)phenyl)amino)benzonitrile;
N-(4-((trans)-2-aminocyclopropyl)phenyl)-3-methoxyaniline;
3-((4-((trans)-2-aminocyclopropyl)phenyl)amino)benzamide; and
pharmaceutically acceptable salts or solvates thereof.
Description
[0001] The invention relates to cyclopropylamine compounds, in
particular the compounds of Formula (I) as described and defined
herein, and their use in therapy, including, e.g., the treatment or
prevention of cancer.
[0002] Aberrant gene expression in affected tissue as compared to
normal tissue is a common characteristic of many human diseases.
This is true for cancer and many neurological diseases which are
characterized by changes in gene expression patterns. Gene
expression patterns are controlled at multiple levels in the cell.
Control of gene expression can occur through modifications of DNA:
DNA promoter methylation is associated with suppression of gene
expression. Several inhibitors of DNA methylation are approved for
clinical use including the blockbuster Vidaza.TM.. Another class of
modifications involve histones which form the protein scaffold that
DNA is normally associated with (coiled around) in eukaryotic
cells. Histones play a crucial role in organizing DNA and the
regulated coiling and uncoiling of DNA around the histones is
critical in controlling gene expression--coiled DNA is typically
not accessible for gene transcription. A number of histone
modification have been discovered including histone acetylation,
histone lysine methylation, histone arginine methylation, histone
ubiquinylation, and histone sumoylation, many of which modify
accessibility to the associated DNA by the cells transcriptional
machinery. These histone marks serve to recruit various protein
complexes involved in transcription and repression. An increasing
number of studies are painting an intricate picture of how various
combinations of histone marks control gene expression in cell-type
specific manner and a new term has been coined to capture this
concept: the histone code.
[0003] The prototypical histone mark is histone acetylation.
Histone acetyl transferase and histone deacetylases are the
catalytic machines involved in modulation of this histone mark
although typically these enzymes are parts of multiprotein
complexes containing other proteins involved in reading and
modifying histone marks. The components of these protein complexes
are typically cell type and typically comprise transcriptional
regulators, repressors, co-reppresors, receptors associated with
gene expression modulation (e.g., estrogen or androgen receptor).
Histone deacetylase inhibitors alter the histone acetylation
profile of chromatin. Accordingly, histone deacetylase inhibitors
like SAHA, TSA, and many others have been shown to alter gene
expression in various in vitro and in vivo animal models.
Clinically, histone deacetylase inhibitor have demonstrated
activity in the cancer setting and are being investigated for
oncology indications as well as for neurological conditions and
other diseases.
[0004] Another modification that is involved in regulating gene
expression is histone methylation including lysine and arginine
methylation. The methylation status of histone lysines has recently
been shown to be important in dynamically regulating gene
expression.
[0005] A group of enzymes known as histone lysine methyl
transferases and histone lysine demethylases are involved histone
lysine modifications. One particular human histone lysine
demethylase enzyme called Lysine Specific Demethylase-1 (LSD1) was
recently discovered (Shi et al. (2004) Cell 119:941) to be involved
in this crucial histone modification. LSD1 has a fair degree of
structural similarity, and amino acid identity/homology to
polyamine oxidases and monoamine oxidases, all of which (i.e.,
MAO-A, MAO-B and LSD1) are flavin dependent amine oxidases which
catalyze the oxidation of nitrogen-hydrogen bonds and/or nitrogen
carbon bonds.
[0006] Several groups have reported LSD1 inhibitors in the
literature. Sharma et al. recently reported a new series of urea
and thiourea analogs based on an earlier series of polyamines which
were shown to inhibit LSD1 and modulate histone methylation and
gene expression in cells (J Med Chem. 2010 PMID: 20568780
[PubMed--as supplied by publisher]). Sharma et al. note that "To
date, only a few existing compounds have been shown to inhibit
LSD1." Some efforts were made to make analogs of the histone
peptide that is methylated by the enzyme, other efforts have
focused on more small molecule like molecules based on known MAO
inhibitors. Gooden et al. reported trans-2-arylcyclopropylamine
analogues that inhibit LSD1 with Ki values in the range of 188-566
micromolar (Gooden et al. ((2008) Bioorg. Med. Chem. Let.
18:3047-3051)). Most of these compounds were more potent against
MAO-A as compared to MAO-B. Ueda et al. ((2009) J. Am. Chem Soc.
131(48):17536-17537) reported cyclopropylamine analogs selective
for LSD1 over MAO-A and MAO-B that were designed based on reported
X-ray crystal structures of these enzymes with a
phenylcyclopropylamine-FAD adduct and a FAD-N-propargyl lysine
peptide. The reported IC50 values for phenylcyclopropylamine were
about 32 micromolar for LSD1 whereas compounds 1 and 2 had values
of 2.5 and 1.9 micromolar respectively.
[0007] Binda et al. examined a series of phenylcyclopropylamine
derivatives in relation to their inhibitory activity against LSD1
and LSD2 as well as examining stereochemical issues in relation to
the cyclopropyl ring (J Am Chem Soc. 2010 May 19; 132(19):6827-33).
Binda et al. reported that their para substituted
phenylcyclopropylamine derivatives are non-selective which as a
group appear to be better MAO-A inhibitors than MAO-B inhibitors.
Furthermore, their inhibitory activities against MAO-A and LSD1
were roughly the same.
[0008] Mimasu et al. disclose a series of phenylcyclopropylamine
derivatives have benzoyl substitutions at the ortho-position
((2010) Biochemistry June 22. [Epub ahead of print] PMID: 20568732
[PubMed--as supplied by publisher]. Ortho-substituted compounds
from this series without a benzoyl group in the ortho-position
e.g., phenyl, alkoxy, or having a combination of ortho- and
para-substitution appeared to be less potent inhibitors of LSD1
than those compounds having benzoyl substituents in the
ortho-position. The most active compounds from this series had a
benzoyl group at the ortho-position and one or two meta fluoro
substitutions: biphenyls like S1310 and compounds having large
groups in the para position were less effective LSD1
inhibitors.
[0009] The phenylcyclopropylamines have been the subject of many
studies designed to elucidate a SAR for MAO inhibition. Kaiser et
al. ((1962) J. Med. Chem. 5:1243-1265); Zirkle et al. ((1962) J.
Med. Chem. 1265-1284; U.S. Pat. Nos. 3,365,458; 3,471,522;
3,532,749) have disclosed the synthesis and activity of a number of
phenylcyclopropylamine related compounds. Other
phenylcyclopropylamine type compounds are disclosed in Bolesov et
al. ((1974) Zhurnal Organicheskoi Khimii 10:8 1661-1669) and
Russian Patent No. 230169 (19681030).
[0010] Studies have been conducted with phenylcyclopropylamine
related compounds to determine selectivity for MAO-A versus MAO-B
since MAO-A inhibitors can cause dangerous side-effects (see e.g.,
Yoshida et al. (2004) Bioorg. Med Chem. 12(10):2645-2652; Hruschka
et al. (2008) Biorg Med Chem. (16):7148-7166; Folks et al. (1983)
J. Clin. Psychopharmacol. (3) 249; and Youdim et al. (1983) Mod.
Probl. Pharmacopsychiatry (19):63).
[0011] In view of the lack of adequate treatments for conditions
such as cancer and neurodegeneration, there is a desperate need for
disease modifying drugs and drugs that work by inhibiting novel
targets. There is a need for the development of better LSD1
selective inhibitors particularly those which selectively inhibit
LSD1 and LSD1 in combination with MAO-B.
[0012] The present invention relates to the identification of
compounds and their use in treating or preventing diseases. The
present invention provides a compound of Formula (I) or a
pharmaceutically acceptable salt or solvate thereof, pharmaceutical
compositions comprising a compound of Formula (I) or a
pharmaceutically acceptable salt or solvate thereof, and a
pharmaceutically acceptable carrier, and their uses for treating or
preventing diseases. One use of the compound of Formula (I) is for
treating or preventing cancer. Another use for the compound of
Formula (I) is to inhibit LSD1. The present invention thus relates
to a compound of Formula (I) or an enantiomer, a diastereomer, or a
mixture thereof, or a pharmaceutically acceptable salt or solvate
thereof for use in treating or preventing cancer and other diseases
associated to LSD1.
[0013] Accordingly, the present invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof and, furthermore, relates to its use in treating or
preventing disease (e.g., human disease):
##STR00002##
[0014] wherein:
[0015] E is --N(R3)-, --S--, --O-- or --X.sup.3.dbd.X.sup.4--;
[0016] X.sup.1 and X.sup.2 are each independently C(R2) or N;
[0017] X.sup.3 and X.sup.4, when present, are each independently
C(R2) or N;
[0018] L1 is --NH-- or --NH--CH.sub.2--;
[0019] G is a cyclyl group (as shown in formula (I), the cyclyl
group G has n substituents R1); each R1 is independently chosen
from alkyl, alkenyl, alkynyl, cyclyl, -L2-cyclyl, -L2-amino,
-L2-hydroxyl, amino, amido, nitro, halo, haloalkyl, haloalkoxy,
cyano, sulfinyl, sulfonyl, sulfonamide, hydroxyl, alkoxy, urea,
carbamate, acyl, or carboxyl;
[0020] each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl,
wherein each R2 group has 1, 2, or 3 independently chosen optional
substituents, and further wherein two R2 groups bound to adjacent
carbon atoms can be taken together to form a heterocyclyl or aryl
group having 1, 2, or 3 independently chosen optional substituents;
wherein said optional substituents are each independently chosen
from alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl,
cycloalkyl, carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl,
aryloxy, heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy,
carbonyl, carboxyl, carboxamido, cyano, halogen, hydroxyl, amino,
aminoalkyl, amidoalkyl, amido, nitro, thiol, alkylthio, arylthio,
sulfinyl, sulfonyl, sulfonamide, urea or carbamate;
[0021] R3 is --H or an (C1-C6)alkyl group;
[0022] each L2 is independently chosen from alkylene or
heteroalkylene; and
[0023] n is 0, 1, 2, 3, 4 or 5.
[0024] Also included within the scope of the invention are all
isomers, including all stereoisomers, and mixtures thereof, of a
compound of formula I, as well as all salts and solvates
thereof.
[0025] Also included within the scope of the invention are all
physical forms (including polymorphic forms and amorphous forms) of
any such compounds.
[0026] The compounds of the invention, in particular the compounds
of Formula (I), are useful in the treatment or prevention of a
disease or disorder, e.g., in a mammal and, in particular, in a
human. The disease or disorder to be treated or prevented is
preferably chosen from cancer, a neurological condition or disease,
or a viral infection.
[0027] In a related aspect, the invention provides a pharmaceutical
composition comprising a compound of Formula (I) or an enantiomer,
a diastereomer, or a mixture thereof, or a pharmaceutically
acceptable salt or solvate thereof as defined below and a
pharmaceutically acceptable carrier. Preferred embodiments of the
compound of Formula (I) for use in the composition are defined and
described herein below in more detail.
[0028] In another aspect, the invention provides a method of
treating or preventing a disease, disorder or condition comprising
administering, to a patient/subject (preferably a human) in need of
such treatment or prevention, a therapeutically effective amount of
a pharmaceutical composition comprising a compound of Formula (I)
as described above or as in the embodiments thereof as described
below, or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier. This aspect can be
reformulated as a compound of Formula (I) as defined above in the
first aspect of the invention for use as a medicine. Accordingly,
the invention relates to the compound of Formula (I) or an
enantiomer, a diastereomer, or a mixture thereof, or a
pharmaceutically acceptable salt or solvate thereof, or a
pharmaceutical composition comprising any of the aforementioned
entities and a pharmaceutically acceptable carrier, for use as a
medicament. In a related aspect, the invention provides a
pharmaceutical composition for use in treating or preventing a
disease, disorder or condition wherein said composition comprises a
therapeutically effective amount of a compound of Formula (I)
sufficient for treating or preventing said disease, disorder or
condition. In a more specific embodiment the invention provides a
compound of Formula (I) or an enantiomer, a diastereomer, or a
mixture thereof, or a pharmaceutically acceptable salt or solvate
thereof, or a pharmaceutical composition comprising any of the
aforementioned entities and a pharmaceutically acceptable carrier
for use in the treatment or prevention of a disease associated with
LSD1. In another embodiment, the invention provides the use of a
compound of Formula (I) or an enantiomer, a diastereomer, or a
mixture thereof, or a pharmaceutically acceptable salt or solvate
thereof, for the manufacture of a medicament for the treatment or
prevention of a disease associated with LSD1.
[0029] In yet another aspect, the invention provides a method of
inhibiting LSD1 activity comprising administering, to a patient in
need of such treatment, a therapeutically effective amount of a
pharmaceutical composition comprising a compound of Formula (I) or
a pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier sufficient to inhibit LSD1 activity. Preferably
the patient is a human. This aspect can be reformulated as a
compound of Formula (I) as herein defined for use as a LSD1
inhibitor. In a related aspect, a method for treating an individual
is provided, said method comprising identifying an individual in
need of treatment or prevention and administering to said
individual a therapeutically effective amount of a compound of
Formula (I). In a preferred aspect, the therapeutically effective
amount of a compound of Formula (I) is an amount sufficient to
inhibit LSD1. In another preferred aspect, the therapeutically
effective amount is an amount sufficient to modulate histone
methylation levels. In another preferred aspect, the
therapeutically effective amount is an amount sufficient to
modulate histone-3 lysine-4 methylation levels. In another
preferred aspect, the therapeutically effective amount is an amount
sufficient to modulate histone-3 lysine-9 methylation levels. In
another preferred aspect, the therapeutically effective amount is
an amount sufficient to modulate gene expression levels. Preferred
embodiments of the compounds of Formula (I) for use in the
composition and method of this aspect of the invention are as
described in more detail herein.
[0030] In again another aspect, the invention provides a method of
treating or preventing cancer comprising administering, to a
patient (e.g., a human) in need of such treatment or prevention, a
therapeutically effective amount of a pharmaceutical composition
comprising a compound of Formula (I) as defined above or as defined
in the embodiments described in more detail herein, and a
pharmaceutically acceptable carrier. This aspect can be
reformulated as a compound of Formula (I) as defined above in the
first aspect of the invention for use in the treatment or
prevention of cancer. In a related aspect, the invention provides
the use of a compound of Formula (I) as defined above in the first
aspect of the invention for the manufacture of a medicament for the
treatment or prevention of cancer. In a related aspect, the
invention provides a pharmaceutical composition for use in treating
or preventing cancer wherein said composition comprises a
therapeutically effective amount of a compound of Formula (I)
sufficient for treating or preventing cancer. In another related
aspect, the invention provides a compound of Formula (I) or a
pharmaceutical composition for use in the treatment or prevention
of a cancer wherein said cancer is chosen from breast cancer, lung
cancer, prostate cancer, colorectal cancer, brain cancer, skin
cancer, blood cancer (e.g., leukemia) and lymphoma, wherein said
composition comprises a therapeutically effective amount of a
compound of Formula (I) sufficient for treating or preventing said
cancer. In a preferred aspect, the therapeutically effective amount
of a compound of Formula (I) is an amount sufficient to inhibit
LSD1. In another preferred aspect, the therapeutically effective
amount is an amount sufficient to modulate histone methylation
levels. In another preferred aspect, the therapeutically effective
amount is an amount sufficient to modulate histone-3 lysine-4
methylation levels. In another preferred aspect, the
therapeutically effective amount is an amount sufficient to
modulate histone-3 lysine-9 methylation levels. In another
preferred aspect, the therapeutically effective amount is an amount
sufficient to modulate gene expression levels
[0031] In again another aspect, the invention provides a method of
treating or preventing a neurological disease or condition
comprising administering, to a patient (e.g., a human) in need of
such treatment or prevention, a therapeutically effective amount of
a pharmaceutical composition comprising a compound of Formula (I)
as defined above or as defined in the embodiments described in more
detail herein, and a pharmaceutically acceptable carrier. This
aspect can be reformulated as a compound of Formula (I) as defined
above for use in the treatment or prevention of a neurological
condition or disease. This a related aspect, the invention provides
the use of a compound of Formula (I) as defined above for the
manufacture of a medicament for the treatment or prevention of a
neurological condition or disease. In a related aspect, the
invention provides a pharmaceutical composition for use in treating
or preventing a neurological condition or disease wherein said
composition comprises a therapeutically effective amount of a
compound of Formula (I) sufficient for treating or preventing said
neurological disease or condition. In another related aspect, the
invention provides a compound of Formula (I) or a pharmaceutical
composition for use in the treatment or prevention of a
neurological disease or condition wherein said neurological disease
or condition is chosen from depression, Alzheimer disease,
Huntington disease, Parkinson disease, or Dementia with Lewy
Bodies, wherein said composition comprises a therapeutically
effective amount of a compound of Formula (I) sufficient for
treating or preventing said disease or condition. In a preferred
aspect, the therapeutically effective amount of a compound of
Formula (I) is an amount sufficient to inhibit LSD1. In another
preferred aspect, the therapeutically effective amount is an amount
sufficient to modulate histone methylation levels. In another
preferred aspect, the therapeutically effective amount is an amount
sufficient to modulate histone-3 lysine-4 methylation levels. In
another preferred aspect, the therapeutically effective amount is
an amount sufficient to modulate histone-3 lysine-9 methylation
levels. In another preferred aspect, the therapeutically effective
amount is an amount sufficient to modulate gene expression
levels.
[0032] Thus, in one embodiment of the invention, the pharmaceutical
composition comprising a LSD1 inhibitor of Formula (I), or a
pharmaceutically acceptable salt thereof is useful for treating
and/or preventing a disease in an individual. In one aspect, a
therapeutically effective amount of the composition is administered
to an individual, the amount being sufficient to prevent or treat a
disease. In a more specific aspect, the disease is cancer. In an
even more specific aspect, the disease is a cancer chosen from
prostate cancer, brain cancer, colorectal cancer, lung cancer,
breast cancer, skin cancer, blood cancer (e.g., leukemia), or
lymphoma. In one specific aspect, the cancer is prostate cancer. In
one specific aspect, the cancer is lung cancer. In one specific
aspect, the cancer is brain cancer. In one specific aspect, the
cancer is blood cancer (e.g., leukemia). In one specific aspect,
the cancer is breast cancer. In one specific aspect, the cancer is
colorectal cancer. In one specific aspect, the cancer is lymphoma.
In another preferred aspect, the therapeutically effective amount
is an amount sufficient to inhibit LSD1. In another preferred
aspect, the therapeutically effective amount is an amount
sufficient to modulate histone methylation levels. In another
preferred aspect, the therapeutically effective amount is an amount
sufficient to modulate histone-3 lysine-4 methylation levels. In
another preferred aspect, the therapeutically effective amount is
an amount sufficient to modulate histone-3 lysine-9 methylation
levels. In another preferred aspect, the therapeutically effective
amount is an amount sufficient to modulate gene expression
levels.
[0033] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention pertains.
Although methods and materials similar or equivalent to those
described herein can be used in the practice or testing of the
present invention, suitable methods and materials are described
below. In case of conflict, the present specification, including
definitions, will control. In addition, the materials, methods, and
examples are illustrative only and not intended to be limiting.
[0034] Other features and advantages of the invention will be
apparent from the following detailed description, and from the
claims.
[0035] The present invention relates to the identification of
compounds and their use in treating or preventing diseases. The
present invention provides compounds of Formula (I) or salts and
solvates thereof, preferably pharmaceutically acceptable salts or
solvates thereof, pharmaceutical compositions comprising a compound
of Formula (I) or a pharmaceutically acceptable salt or solvate
thereof and a pharmaceutically acceptable carrier, and their use
for treating or preventing diseases. One use of the compounds of
Formula (I) is for treating or preventing cancer. In particular it
was found that the cyclylpropylamine (in particular,
phenylcyclopropylamine and pyridinylcyclopropylamine) compounds of
Formula (I) are unexpectedly potent LSD1 inhibitors. The compounds
of Formula (I) as described and defined herein are generally better
inhibitors of LSD1 by a factor of about 20 or more as compared to
tranylcypromine, with improved selectivity against MAO-A.
[0036] Accordingly, the invention provides a compound of Formula
(I) or a pharmaceutically acceptable salt or solvate thereof and,
furthermore, relates to its use in treating or preventing a disease
or disorder (such as, e.g., cancer):
##STR00003##
[0037] The compound of Formula (I) is described in more detail in
the following.
[0038] E is --N(R3)-, --S--, --O-- or --X.sup.3.dbd.X.sup.4--.
Preferably, E is --X.sup.3.dbd.X.sup.4--.
[0039] X.sup.1 and X.sup.2 are each independently C(R2) or N.
[0040] X.sup.3 and X.sup.4, when present, are each independently
C(R2) or N.
[0041] In a preferred embodiment, the ring moiety containing E,
X.sup.1 and X.sup.2 is chosen from: [0042] (i) a ring wherein E is
--X.sup.3.dbd.X.sup.4--, one of X.sup.1, X.sup.2, X.sup.3, and
X.sup.4 is N or C(R2) and the other ones of X.sup.1, X.sup.2,
X.sup.3, and X.sup.4 are each independently C(R2); [0043] (ii) a
ring wherein E is --S-- and X.sup.1 and X.sup.2 are independently
C(R2), [0044] (iii) a ring wherein E is --S--, X.sup.1 is N and
X.sup.2 is C(R2); and [0045] (iv) a ring wherein E is --S--,
X.sup.1 is C(R2) and X.sup.2 is N.
[0046] Preferably, E is --X.sup.3.dbd.X.sup.4--, one of X.sup.1,
X.sup.2, X.sup.3, and X.sup.4 is N or C(R2) and the other ones of
X.sup.1, X.sup.2, X.sup.3, and X.sup.4 are each independently C(R2)
(in particular, the other ones of X.sup.1, X.sup.2, X.sup.3, and
X.sup.4 may each be CH). Accordingly, it is preferred that the ring
moiety comprising E, X.sup.1 and X.sup.2 is a pyridinyl or phenyl
ring.
[0047] More preferably, one of X.sup.1, X.sup.2, X.sup.3, and
X.sup.4 is N and the other ones of X.sup.1, X.sup.2, X.sup.3, and
X.sup.4 are each independently C(R2) (in particular, the other ones
of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 may each be CH).
Accordingly, it is preferred that the ring moiety comprising E,
X.sup.1 and X.sup.2 is a pyridinyl ring.
[0048] In a more preferred embodiment, X.sup.1 is N, and X.sup.2,
X.sup.3 and X.sup.4 are each independently C(R2) (in particular,
X.sup.2, X.sup.3 and X.sup.4 may each be CH). In another preferred
embodiment, X.sup.2 is N and X.sup.1, X.sup.3 and X.sup.4 are each
independently C(R2) (in particular, X.sup.1, X.sup.3 and X.sup.4
may each be CH).
[0049] L1 is --NH-- or --NH--CH.sub.2--.
[0050] It is to be understood that the group --NH--CH.sub.2-- can
be present in either orientation. Accordingly, if L1 is
--NH--CH.sub.2--, the NH moiety in --NH--CH.sub.2-- can be bound to
the ring moiety containing E, X.sup.1 and X.sup.2, and the CH.sub.2
moiety in --NH--CH.sub.2-- can be bound to the group G.
Alternatively, the NH moiety in --NH--CH.sub.2-- can be bound to
the group G, and the CH.sub.2 moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2.
[0051] If L1 is --NH--CH.sub.2--, it is preferred that the NH
moiety in --NH--CH.sub.2-- is bound to the ring moiety containing
E, X.sup.1 and X.sup.2, and that the CH.sub.2 moiety in
--NH--CH.sub.2-- is bound to the group G.
[0052] Preferably L1 is --NH-- or --NH--CH.sub.2-- wherein the NH
moiety in --NH--CH.sub.2-- is bound to the ring moiety containing
E, X.sup.1 and X.sup.2 and the CH.sub.2 moiety in --NH--CH.sub.2--
is bound to the group G. In another embodiment, L1 is --NH--. In
another embodiment L1 is --NH--CH.sub.2-- wherein the NH moiety in
--NH--CH.sub.2-- is bound to the ring moiety containing E, X.sup.1
and X.sup.2 and the CH.sub.2 moiety in --NH--CH.sub.2-- is bound to
the group G.
[0053] G is a cyclyl group. As shown in Formula (I), the cyclyl
group G has n substituents R1. Preferably, G is an aryl group or a
heterocyclyl group, and more preferably G is an aryl or heteroaryl
group.
[0054] In one preferred embodiment, G is a heterocyclyl group, more
preferably G is a heteroaryl group (such as, e.g., thiophenyl,
benzothiophenyl, indolyl or indazolyl), and even more preferably G
is indolyl (in particular but without limitation, 1H-indolyl, such
as, e.g., 1-H-indol-7-yl) or indazolyl (in particular but without
limitation, 1H-indazolyl, such as, e.g., 1H-indazol-7-yl).
[0055] In another preferred embodiment, G is an aryl group (such
as, e.g., phenyl or naphthyl), and more preferably G is phenyl.
[0056] In another embodiment, G is phenyl, indolyl or indazolyl,
and preferably G is phenyl, 1H-indolyl or 1H-indazolyl.
[0057] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or
carboxyl.
[0058] Preferably, each R1 is independently chosen from alkyl,
alkynyl, aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy,
cyano, heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide,
hydroxyl, or alkoxy.
[0059] More preferably, each R1 is independently chosen from lower
alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo, lower
haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or
alkoxy.
[0060] More preferably, each R is independently chosen from lower
alkyl, lower alkynyl, amido, halo, lower haloalkyl, cyano,
hydroxyl, or alkoxy.
[0061] Even more preferably, each R1 is independently chosen from
--CF.sub.3, --OCH.sub.3, halo (in particular, --Cl), --CN,
--CH.sub.3, --OH, ethynyl or --C(.dbd.O)NH.sub.2.
[0062] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms can thus be X.sup.1 and X.sup.2 or can be
X.sup.1 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents.
[0063] Said optional substituents (i.e., said optional substituents
bound to the R2 group or said optional substituents bound to the
heterocyclyl or aryl group formed from two R2 groups bound to
adjacent carbon atoms) are each independently chosen from alkyl,
alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0064] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above).
[0065] More preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido.
[0066] Even more preferably, each R2 is independently chosen from
--H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
chloro, fluoro, --CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or
--OCH.sub.3.
[0067] Preferably, each R2 is --H or 1 or 2 groups R2 are not --H.
In one embodiment, each R2 is --H.
[0068] It is to be understood that, if R2 is H, this group does not
have any optional substituents. In another embodiment, 1 or 2
groups R2 are different from --H.
[0069] R3 is --H or an (C1-C6)alkyl group.
[0070] Preferably, R3 is --H or (C1-C4)alkyl. More preferably, R3
is --H, methyl or ethyl. Even more preferably, R3 is --H.
[0071] Each L2 is independently chosen from alkylene or
heteroalkylene.
[0072] Said alkylene is, for example, a (C1-C6)alkylene (including,
e.g., methylene, ethylene, propylene, butylene, pentylene, or
hexylene), in particular a linear (C1-C6)alkylene. Said
heteroalkylene is, for example, chosen from --CH.sub.2OCH.sub.2--,
--CH.sub.2SCH.sub.2--, --CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0073] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0074] It is to be understood that, if n is 0, the group G is not
substituted with any group R1 (i.e., the group G is substituted
with hydrogen instead of R1 in that case).
[0075] Preferably, the compound of Formula (I) is in the trans
configuration in respect of the cyclopropyl ring, i.e., the amino
group bound to the cyclopropyl ring and the ring moiety comprising
E, X.sup.1 and X.sup.2, which ring moiety is bound to the
cyclopropyl ring, are in trans orientation in respect of the
cyclopropyl ring. Accordingly, it is preferred that the compound of
Formula (I) is a compound of the following formula:
##STR00004##
or a pharmaceutically acceptable salt or solvate thereof, wherein
E, X.sup.1, X.sup.2, L1 (shown as L.sub.1 in the above formula), G,
R1, and n have the meanings or the preferred meanings described and
defined herein for the compound of Formula (I).
[0076] Preferably, the compound of Formula (I) comprises a racemic
mixture of compounds of Formula (I). Accordingly, it is preferred
that the compound of Formula (I) is a mixture of compounds of
Formula (I) in the (1S,2R) and (1R,2S) configurations in respect of
the cyclopropyl ring, i.e., the amino group bound to the
cyclopropyl ring and the ring moiety comprising E, X.sup.1 and
X.sup.2, which ring moiety is bound to the cyclopropyl ring, are in
(1S, 2R) and (1R, 2S) configuration in respect of the cyclopropyl
ring.
[0077] More preferably, the compound of Formula (I) is in one
enantiomeric configuration. Accordingly, it is preferred that the
compound of Formula (I) is in the (1S, 2R) or in the (1R, 2S)
configuration in respect of the cyclopropyl ring, i.e., the amino
group bound to the cyclopropyl ring and the ring moiety comprising
E, X.sup.1 and X.sup.2, which ring moiety is bound to the
cyclopropyl ring, are in (1S, 2R) or (1R, 2S) orientation in
respect of the cyclopropyl ring. Thus, in one preferred embodiment
the compound of Formula (I) is (1S, 2R) with substantially little
or no (1R,2S) wherein substantially little or no (1R,2S) refers to
a compound of Formula (I) having 90% or more, preferably, 95% or
more, and even more preferably 99% or more (1S,2R) and preferably
less than 10%, more preferably less than 5% and even more
preferably less than 1% (1R,2S). In another preferred embodiment
the compound of Formula (I) is (1R,2S) with substantially little or
no (1S, 2R) wherein substantially little or no (1S,2R) refers to a
compound of Formula (I) having 90% or more, preferably, 95% or
more, and even more preferably 99% or more (1R, 2S) and preferably
less than 10%, more preferably less than 5% and even more
preferably less than 1% (1S,2R).
[0078] Thus, in one embodiment, the invention provides a compound
of Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein L1 is --NH-- and E is --X.sup.3.dbd.X.sup.4--. In
a preferred aspect of this embodiment, X.sup.1 is N and X.sup.2,
X.sup.3 and X.sup.4 are each --CH-- and G is phenyl optionally
having 1, 2, 3, or 4 substituents R1 which are each independently
chosen from alkyl, alkynyl, aryl, amino, amido, nitro, halo,
haloalkyl, haloalkoxy, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. It is furthermore preferred that each
substituent R1 is independently chosen from --CF.sub.3,
--OCH.sub.3, --CI, --CN, --CH.sub.3, --OH, ethynyl or
--C(.dbd.O)NH.sub.2.
[0079] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein L1 is --NH-- and E is --X.sup.3.dbd.X.sup.4--. In
a preferred aspect of this embodiment, X.sup.1 is N and X.sup.2,
X.sup.3 and X.sup.4 are each --CH-- and G is a heterocyclyl.
Preferably G is indolyl or indazolyl.
[0080] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein E is --X.sup.3.dbd.X.sup.4-- and L1 is
--NH--CH.sub.2-- (wherein it is preferred that the NH moiety of
said --NH--CH.sub.2-- is bound to the ring moiety comprising E,
X.sup.1 and X.sup.2, and that the CH.sub.2 moiety of said
--NH--CH.sub.2-- is bound to the group G). In a preferred aspect of
this embodiment, X.sup.1 is N and X.sup.2, X.sup.3 and X.sup.4 are
each --CH-- and G is phenyl optionally having 1, 2, 3, or 4
substituents R1 which are each independently chosen from alkyl,
alkynyl, aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy,
cyano, heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or alkoxy. It
is furthermore preferred that each substituent R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, --Cl, --CN, --CH.sub.3, --OH,
ethynyl or --C(.dbd.O)NH.sub.2.
[0081] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0082] E is --X.sup.3.dbd.X.sup.4--.
[0083] X.sup.1 is N.
[0084] X.sup.2, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X.sup.2, X.sup.3 and X.sup.4 are each CH.
[0085] L1 is --NH--.
[0086] G is phenyl. As shown in Formula (I), the group G has n
substituents R1.
[0087] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0088] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate.
[0089] Preferably, the optional substituents are each independently
chosen from lower alkyl, lower alkanoyl, lower heteroalkyl, lower
heterocyclyl, lower haloalkyl, lower cycloalkyl, lower carbocyclyl,
arylalkoxy, heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy,
lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl,
carboxyl, lower carboxamido, cyano, halogen, hydroxyl, amino,
aminoalkyl, amidoalkyl, amido, nitro, thiol, lower alkylthio, or
arylthio.
[0090] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
[0091] Even more preferably, each R2 is --H.
[0092] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0093] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0094] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus) or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0095] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0096] E is --X.sup.3.dbd.X.sup.4--.
[0097] X.sup.1 is N.
[0098] X.sup.2, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X, X.sup.3 and X.sup.4 are each CH.
[0099] L1 is --NH--.
[0100] G is a heterocyclyl group. Preferably, G is a heteroaryl
group. More preferably, G is selected from thiophenyl,
benzothiophenyl, indolyl or indazolyl. Even more preferably, G is
indolyl (in particular but without limitation, 1H-indolyl, such as,
e.g., 1-H-indol-7-yl) or indazolyl (in particular but without
limitation, 1H-indazolyl, such as, e.g., 1H-indazol-7-yl). As shown
in Formula (I), the group G has n substituents R1.
[0101] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0102] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0103] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
[0104] Even more preferably, each R2 is --H.
[0105] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0106] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0107] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0108] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0109] E is --X.sup.3.dbd.X.sup.4--.
[0110] X.sup.1 is N.
[0111] X.sup.2, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X.sup.2, X.sup.3 and X.sup.4 are each CH.
[0112] L1 is --NH--CH.sub.2--.
[0113] The group --NH--CH.sub.2-- may be present in either
orientation. Accordingly, the NH moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2, and the
CH.sub.2 moiety in --NH--CH.sub.2-- can be bound to the group G.
Alternatively, the NH moiety in --NH--CH.sub.2-- can be bound to
the group G, and the CH.sub.2 moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2.
Preferably, the NH moiety in --NH--CH.sub.2-- is bound to the ring
moiety containing E, X.sup.1 and X.sup.2, and that the CH.sub.2
moiety in --NH--CH.sub.2-- is bound to the group G.
[0114] G is phenyl. As shown in Formula (I), the group G has n
substituents R1.
[0115] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0116] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0117] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0118] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0119] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0120] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0121] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0122] E is --X.sup.3.dbd.X.sup.4--.
[0123] X.sup.1 is N.
[0124] X.sup.2, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X.sup.2, X.sup.3 and X.sup.4 are each CH.
[0125] L1 is --NH--CH.sub.2--.
[0126] The group --NH--CH.sub.2-- may be present in either
orientation. Accordingly, the NH moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2, and the
CH.sub.2 moiety in --NH--CH.sub.2-- can be bound to the group G.
Alternatively, the NH moiety in --NH--CH.sub.2-- can be bound to
the group G, and the CH.sub.2 moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2.
Preferably, the NH moiety in --NH--CH.sub.2-- is bound to the ring
moiety containing E, X.sup.1 and X.sup.2, and that the CH.sub.2
moiety in --NH--CH.sub.2-- is bound to the group G.
[0127] G is a heterocyclyl group. Preferably, G is a heteroaryl
group. More preferably, G is selected from thiophenyl,
benzothiophenyl, indolyl or indazolyl. Even more preferably, G is
indolyl (in particular but without limitation, 1H-indolyl, such as,
e.g., 1-H-indol-7-yl) or indazolyl (in particular but without
limitation, 1H-indazolyl, such as, e.g., 1H-indazol-7-yl). As shown
in Formula (I), the group G has n substituents R1.
[0128] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy.
[0129] More preferably, each R1 is independently chosen from lower
alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo, lower
haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or
alkoxy. Even more preferably, each R1 is independently chosen from
--CF.sub.3, --OCH.sub.3, halo (in particular, --Cl), --CN,
--CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0130] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0131] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
[0132] Even more preferably, each R2 is --H.
[0133] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0134] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0135] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0136] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0137] E is --X.sup.3.dbd.X.sup.4--.
[0138] X.sup.2 is N.
[0139] X.sup.1, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X.sup.1, X.sup.3 and X.sup.4 are each CH.
[0140] L1 is --NH--.
[0141] G is phenyl. As shown in Formula (I), the group G has n
substituents R1.
[0142] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy.
[0143] More preferably, each R1 is independently chosen from lower
alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo, lower
haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or
alkoxy. Even more preferably, each R1 is independently chosen from
--CF.sub.3, --OCH.sub.3, halo (in particular, --Cl), --CN,
--CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0144] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0145] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0146] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0147] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0148] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0149] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0150] E is --X.sup.3.dbd.X.sup.4--.
[0151] X.sup.2 is N.
[0152] X.sup.1, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X.sup.1, X.sup.3 and X.sup.4 are each CH.
[0153] L1 is --NH--.
[0154] G is a heterocyclyl group. Preferably, G is a heteroaryl
group. More preferably, G is selected from thiophenyl,
benzothiophenyl, indolyl or indazolyl. Even more preferably, G is
indolyl (in particular but without limitation, 1H-indolyl, such as,
e.g., 1-H-indol-7-yl) or indazolyl (in particular but without
limitation, 1H-indazolyl, such as, e.g., 1H-indazol-7-yl). As shown
in Formula (I), the group G has n substituents R1.
[0155] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy.
[0156] More preferably, each R1 is independently chosen from lower
alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo, lower
haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or
alkoxy. Even more preferably, each R1 is independently chosen from
--CF.sub.3, --OCH.sub.3, halo (in particular, --Cl), --CN,
--CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0157] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate.
[0158] Preferably, the optional substituents are each independently
chosen from lower alkyl, lower alkanoyl, lower heteroalkyl, lower
heterocyclyl, lower haloalkyl, lower cycloalkyl, lower carbocyclyl,
arylalkoxy, heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy,
lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl,
carboxyl, lower carboxamido, cyano, halogen, hydroxyl, amino,
aminoalkyl, amidoalkyl, amido, nitro, thiol, lower alkylthio, or
arylthio.
[0159] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0160] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene can, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0161] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0162] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0163] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0164] E is --X.sup.3.dbd.X.sup.4--.
[0165] X.sup.2 is N.
[0166] X.sup.1, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X.sup.1, X.sup.3 and X.sup.4 are each CH.
[0167] L1 is --NH--CH.sub.2--.
[0168] The group --NH--CH.sub.2-- may be present in either
orientation. Accordingly, the NH moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2, and the
CH.sub.2 moiety in --NH--CH.sub.2-- can be bound to the group G.
Alternatively, the NH moiety in --NH--CH.sub.2-- can be bound to
the group G, and the CH.sub.2 moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2.
Preferably, the NH moiety in --NH--CH.sub.2-- is bound to the ring
moiety containing E, X.sup.1 and X.sup.2, and that the CH.sub.2
moiety in --NH--CH.sub.2-- is bound to the group G.
[0169] G is phenyl. As shown in Formula (I), the group G has n
substituents R1.
[0170] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0171] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0172] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0173] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0174] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0175] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0176] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, X.sup.3, X.sup.4,
L1, G, R1, R2, L2, and n have the following meanings.
[0177] E is --X.sup.1.dbd.X.sup.4--.
[0178] X.sup.2 is N.
[0179] X.sup.1, X.sup.3 and X.sup.4 are each independently C(R2).
Preferably, X.sup.1, X.sup.3 and X.sup.4 are each CH.
[0180] L1 is --NH--CH.sub.2--.
[0181] The group --NH--CH.sub.2-- may be present in either
orientation. Accordingly, the NH moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2, and the
CH.sub.2 moiety in --NH--CH.sub.2-- can be bound to the group G.
Alternatively, the NH moiety in --NH--CH.sub.2-- can be bound to
the group G, and the CH.sub.2 moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2.
Preferably, the NH moiety in --NH--CH.sub.2-- is bound to the ring
moiety containing E, X.sup.1 and X.sup.2, and that the CH.sub.2
moiety in --NH--CH.sub.2-- is bound to the group G.
[0182] G is a heterocyclyl group. Preferably, G is a heteroaryl
group. More preferably, G is selected from thiophenyl,
benzothiophenyl, indolyl or indazolyl. Even more preferably, G is
indolyl (in particular but without limitation, 1H-indolyl, such as,
e.g., l-H-indol-7-yl) or indazolyl (in particular but without
limitation, 1H-indazolyl, such as, e.g., 1H-indazol-7-yl). As shown
in Formula (I), the group G has n substituents R1.
[0183] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy.
[0184] More preferably, each R1 is independently chosen from lower
alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo, lower
haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or
alkoxy. Even more preferably, each R1 is independently chosen from
--CF.sub.3, --OCH.sub.3, halo (in particular, --Cl), --CN,
--CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0185] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2;
the adjacent carbon atoms may thus be X.sup.1 and X.sup.2 or may be
X.sup.3 and X.sup.4) can be taken together to form a heterocyclyl
or aryl group having 1, 2, or 3 independently chosen optional
substituents. Said optional substituents (i.e., said optional
substituents bound to the R2 group or said optional substituents
bound to the heterocyclyl or aryl group formed from two R2 groups
bound to adjacent carbon atoms) are each independently chosen from
alkyl, alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0186] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0187] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0188] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. Even more preferably, n is 1
or 2. Even more preferably, n is 1.
[0189] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0190] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, L1, G, R1, R2, R3,
L2, and n have the following meanings.
[0191] E is --N(R3)-, --S--, or --O--.
[0192] R3 is --H or (C1-C6)alkyl. Preferably, R3 is --H or
(C1-C4)alkyl. More preferably, R3 is --H, methyl or ethyl. Even
more preferably, R3 is --H.
[0193] X.sup.1 and X.sup.2 are each independently C(R2) or N.
Preferably, one of X.sup.1 and X.sup.2 is C(R2) or N, and the other
one of X.sup.1 and X.sup.2 is independently C(R2). More preferably,
one of X.sup.1 and X.sup.2 is CH or N, and the other one of X.sup.1
and X.sup.2 is CH.
[0194] L1 is --NH--.
[0195] G is phenyl. As shown in Formula (I), the group G has n
substituents R1.
[0196] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0197] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2)
can be taken together to form a heterocyclyl or aryl group having
1, 2, or 3 independently chosen optional substituents. Said
optional substituents (i.e., said optional substituents bound to
the R2 group or said optional substituents bound to the
heterocyclyl or aryl group formed from two R2 groups bound to
adjacent carbon atoms) are each independently chosen from alkyl,
alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0198] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0199] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0200] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. In particular, n may be 0.
[0201] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0202] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, L1, G, R1, R2, R3,
L2, and n have the following meanings.
[0203] E is --N(R3)-, --S--, or --O--.
[0204] R3 is --H or (C1-C6)alkyl. Preferably, R3 is --H or
(C1-C4)alkyl. More preferably, R3 is --H, methyl or ethyl. Even
more preferably, R3 is --H.
[0205] X.sup.1 and X.sup.2 are each independently C(R2) or N.
Preferably, one of X.sup.1 and X.sup.2 is C(R2) or N, and the other
one of X.sup.1 and X.sup.2 is independently C(R2). More preferably,
one of X.sup.1 and X.sup.2 is CH or N, and the other one of X.sup.1
and X.sup.2 is CH.
[0206] L1 is --NH--.
[0207] G is a heterocyclyl group. Preferably, G is a heteroaryl
group. More preferably, G is selected from thiophenyl,
benzothiophenyl, indolyl or indazolyl. Even more preferably, G is
indolyl (in particular but without limitation, 1H-indolyl, such as,
e.g., 1-H-indol-7-yl) or indazolyl (in particular but without
limitation, 1H-indazolyl, such as, e.g., 1H-indazol-7-yl). As shown
in Formula (I), the group G has n substituents R1.
[0208] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0209] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2)
can be taken together to form a heterocyclyl or aryl group having
1, 2, or 3 independently chosen optional substituents. Said
optional substituents (i.e., said optional substituents bound to
the R2 group or said optional substituents bound to the
heterocyclyl or aryl group formed from two R2 groups bound to
adjacent carbon atoms) are each independently chosen from alkyl,
alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0210] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0211] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0212] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. In particular, n may be 0.
[0213] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0214] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, L1, G, R1, R2, R3,
L2, and n have the following meanings.
[0215] E is --N(R3)-, --S--, or --O--.
[0216] R3 is --H or (C1-C6)alkyl. Preferably, R3 is --H or
(C1-C4)alkyl. More preferably, R3 is --H, methyl or ethyl. Even
more preferably, R3 is --H.
[0217] X.sup.1 and X.sup.2 are each independently C(R2) or N.
Preferably, one of X.sup.1 and X.sup.2 is C(R2) or N, and the other
one of X.sup.1 and X.sup.2 is independently C(R2). More preferably,
one of X.sup.1 and X.sup.2 is CH or N, and the other one of X.sup.1
and X.sup.2 is CH.
[0218] L1 is --NH--CH.sub.2--.
[0219] The group --NH--CH.sub.2-- may be present in either
orientation. Accordingly, the NH moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2, and the
CH.sub.2 moiety in --NH--CH.sub.2-- can be bound to the group G.
Alternatively, the NH moiety in --NH--CH.sub.2-- can be bound to
the group G, and the CH.sub.2 moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2.
Preferably, the NH moiety in --NH--CH.sub.2-- is bound to the ring
moiety containing E, X.sup.1 and X.sup.2, and that the CH.sub.2
moiety in --NH--CH.sub.2-- is bound to the group G.
[0220] G is phenyl. As shown in Formula (I), the group G has n
substituents R1.
[0221] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0222] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2)
can be taken together to form a heterocyclyl or aryl group having
1, 2, or 3 independently chosen optional substituents. Said
optional substituents (i.e., said optional substituents bound to
the R2 group or said optional substituents bound to the
heterocyclyl or aryl group formed from two R2 groups bound to
adjacent carbon atoms) are each independently chosen from alkyl,
alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0223] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0224] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0225] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. In particular, n may be 0.
[0226] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0227] In one embodiment, the invention provides a compound of
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the groups E, X.sup.1, X.sup.2, L1, G, R1, R2, R3,
L2, and n have the following meanings.
[0228] E is --N(R3)-, --S--, or --O--.
[0229] R3 is --H or (C1-C6)alkyl. Preferably, R3 is --H or
(C1-C4)alkyl. More preferably, R3 is --H, methyl or ethyl. Even
more preferably, R3 is --H.
[0230] X.sup.1 and X.sup.2 are each independently C(R2) or N.
Preferably, one of X.sup.1 and X.sup.2 is C(R2) or N, and the other
one of X.sup.1 and X.sup.2 is independently C(R2). More preferably,
one of X.sup.1 and X.sup.2 is CH or N, and the other one of X.sup.1
and X.sup.2 is CH.
[0231] L1 is --NH--CH.sub.2--.
[0232] The group --NH--CH.sub.2-- may be present in either
orientation. Accordingly, the NH moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2, and the
CH.sub.2 moiety in --NH--CH.sub.2-- can be bound to the group G.
Alternatively, the NH moiety in --NH--CH.sub.2-- can be bound to
the group G, and the CH.sub.2 moiety in --NH--CH.sub.2-- can be
bound to the ring moiety containing E, X.sup.1 and X.sup.2.
Preferably, the NH moiety in --NH--CH.sub.2-- is bound to the ring
moiety containing E, X.sup.1 and X.sup.2, and that the CH.sub.2
moiety in --NH--CH.sub.2-- is bound to the group G.
[0233] G is a heterocyclyl group. Preferably, G is a heteroaryl
group. More preferably, G is selected from thiophenyl,
benzothiophenyl, indolyl or indazolyl. Even more preferably, G is
indolyl (in particular but without limitation, 1H-indolyl, such as,
e.g., 1-H-indol-7-yl) or indazolyl (in particular but without
limitation, 1H-indazolyl, such as, e.g., 1H-indazol-7-yl). As shown
in Formula (I), the group G has n substituents R1.
[0234] Each R1 is independently chosen from alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Preferably, each R1 is independently chosen from alkyl, alkynyl,
aryl, amino, amido, nitro, halo, haloalkyl, haloalkoxy, cyano,
heterocyclyl (e.g., heteroaryl), sulfonyl, sulfonamide, hydroxyl,
or alkoxy. More preferably, each R1 is independently chosen from
lower alkyl, lower alkynyl, lower aryl, amino, amido, nitro, halo,
lower haloalkyl, cyano, heterocyclyl, sulfonyl, sulfonamide,
hydroxyl, or alkoxy. Even more preferably, each R1 is independently
chosen from --CF.sub.3, --OCH.sub.3, halo (in particular, --Cl),
--CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0235] Each R2 is independently chosen from --H, alkyl, alkenyl,
alkynyl, cyclyl, -L2-cyclyl, -L2-amino, -L2-hydroxyl, amino, amido,
nitro, halo, haloalkyl, haloalkoxy, cyano, sulfinyl, sulfonyl,
sulfonamide, hydroxyl, alkoxy, urea, carbamate, acyl, or carboxyl.
Each R2 group has 1, 2, or 3 independently chosen optional
substituents (i.e., each R2 group optionally has 1, 2, or 3
independently chosen substituents as defined below). Furthermore,
two R2 groups bound to adjacent carbon atoms (i.e., adjacent ring
carbon atoms of the ring moiety comprising E, X.sup.1 and X.sup.2)
can be taken together to form a heterocyclyl or aryl group having
1, 2, or 3 independently chosen optional substituents. Said
optional substituents (i.e., said optional substituents bound to
the R2 group or said optional substituents bound to the
heterocyclyl or aryl group formed from two R2 groups bound to
adjacent carbon atoms) are each independently chosen from alkyl,
alkanoyl, heteroalkyl, heterocyclyl, haloalkyl, cycloalkyl,
carbocyclyl, arylalkoxy, heterocyclylalkoxy, aryl, aryloxy,
heterocyclyloxy, alkoxy, haloalkoxy, oxo, acyloxy, carbonyl,
carboxyl, carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, alkylthio, arylthio, sulfinyl,
sulfonyl, sulfonamide, urea or carbamate. Preferably, the optional
substituents are each independently chosen from lower alkyl, lower
alkanoyl, lower heteroalkyl, lower heterocyclyl, lower haloalkyl,
lower cycloalkyl, lower carbocyclyl, arylalkoxy,
heterocyclylalkoxy, aryl, aryloxy, heterocyclyloxy, lower alkoxy,
lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower
carboxamido, cyano, halogen, hydroxyl, amino, aminoalkyl,
amidoalkyl, amido, nitro, thiol, lower alkylthio, or arylthio.
[0236] Preferably, each R2 is independently chosen from --H,
hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents (as defined and described
herein above). More preferably, each R2 is independently chosen
from --H, hydroxyl, haloalkyl, alkoxy, halo, amido, arylalkyl,
heterocyclylalkyl, arylalkoxy, or heterocyclylalkoxy, wherein each
R2 has 1, 2, or 3 optional substituents independently chosen from
lower alkyl, lower haloalkyl, lower haloalkoxy, amino(C1-C6)alkyl,
halo, lower alkoxy, or amido. Even more preferably, each R2 is
independently chosen from --H, hydroxyl, haloalkyl, alkoxy, halo,
amido, arylalkyl, heterocyclylalkyl, arylalkoxy, or
heterocyclylalkoxy, wherein each R2 has 1, 2, or 3 optional
substituents independently chosen from chloro, fluoro,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, or --OCH.sub.3.
Even more preferably, each R2 is --H.
[0237] Each L2 is independently chosen from alkylene or
heteroalkylene. Said alkylene is, for example, a (C1-C6)alkylene
(including, e.g., methylene, ethylene, propylene, butylene,
pentylene, or hexylene), in particular a linear (C1-C6)alkylene.
Said heteroalkylene is, for example, chosen from
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--. Preferably, each L2 is
independently chosen from (C1-C6)alkylene, more preferably from
linear (C1-C6)alkylene.
[0238] n is 0, 1, 2, 3, 4 or 5. Preferably, n is 0, 1, 2, 3, or 4.
More preferably, n is 0, 1, 2, or 3. In particular, n may be 0.
[0239] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus), or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0240] In one preferred embodiment, the invention provides a
compound of Formula (I) or a pharmaceutically acceptable salt or
solvate thereof, wherein:
[0241] E is --X.sup.3.dbd.X.sup.4--.
[0242] X.sup.1 is N.
[0243] X.sup.2, X.sup.3 and X.sup.4 are each CH.
[0244] L1 is --NH-- or --NH--CH.sub.2--.
[0245] G is a substituted phenyl with one substituent R1, or G is
indolyl or indazolyl.
[0246] R1 is independently chosen from lower alkyl, lower alkynyl,
lower aryl, amino, amido, nitro, halo, lower haloalkyl, cyano,
heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or alkoxy.
Preferably, R1 is --CF.sub.3, --OCH.sub.3, halo (in particular,
--Cl), --CN, --CH.sub.3, --OH, ethynyl, or --C(.dbd.O)NH.sub.2.
[0247] In another preferred embodiment, the invention provides a
compound of Formula (I) or a pharmaceutically acceptable salt or
solvate thereof, wherein:
[0248] E is --X.sup.3.dbd.X.sup.4--.
[0249] X.sup.1 is N or CH.
[0250] X.sup.2, X.sup.3 and X.sup.4 are each CH.
[0251] L1 is --NH-- or --NH--CH.sub.2--.
[0252] G is a substituted phenyl with one substituent R1, or G is
indolyl or indazolyl.
[0253] R1 is independently chosen from lower alkyl, lower alkynyl,
lower aryl, amino, amido, nitro, halo, lower haloalkyl, cyano,
heterocyclyl, sulfonyl, sulfonamide, hydroxyl, or alkoxy.
[0254] Preferably, R1 is --CF.sub.3, --OCH.sub.3, halo (in
particular, --Cl), --CN, --CH.sub.3, --OH, ethynyl, or
--C(.dbd.O)NH.sub.2.
[0255] The invention further relates to the compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, as
defined in the above described embodiment, for use as a medicament,
for use in the treatment or prevention of cancer (such as, e.g.,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer, leukemia or lymphoma), for
use in the treatment or prevention of a neurological disease or
condition (such as, e.g., depression, Alzheimer disease, Huntington
disease, Parkinson disease, or Dementia with Lewy Bodies), for use
in the treatment or prevention of a viral infection (such as, e.g.,
a viral infection caused by and/or associated with HIV, or a
herpesvirus infection which may be caused by and/or may be
associated with a herpesvirus chosen from HSV-1, HSV-2, or
Epstein-Barr virus) or for use in treating or preventing viral
reactivation after latency (such as, e.g., reactivation of a
herpesvirus after latency, or reactivation of a herpesvirus chosen
from HSV-1, HSV-2, and Epstein-Barr virus).
[0256] In one aspect, the invention provides a stereoisomer or a
mixture thereof, of a compound of Formula (I).
[0257] In another aspect, the invention relates to a derivative or
analog of a compound of Formula (I).
[0258] In yet another aspect, the invention relates to a solvate or
polymorph of a compound of Formula (I).
[0259] In another aspect, the invention relates to a salt of a
compound of formula (I).
[0260] In yet another aspect, the invention relates to a prodrug of
a compound of Formula (I).
[0261] In yet another aspect, the invention relates to a metabolite
of a compound of Formula (I).
[0262] In another aspect, the invention provides a method of
treating or preventing a disease or condition comprising
administering, to a patient (preferably, a human) in need of such
treatment or prevention, a therapeutically effective amount of a
pharmaceutical composition comprising a compound of Formula (I) as
defined above, or a pharmaceutically acceptable salt or solvate
thereof and a pharmaceutically acceptable carrier. This aspect can
be reformulated as a compound of Formula (I) or a pharmaceutically
acceptable salt or solvate thereof for use as a medicine. In a
related aspect, the invention provides a pharmaceutical composition
for use in treating or preventing a disease or condition wherein
said composition comprises a therapeutically effective amount of a
compound of Formula (I) sufficient for treating or preventing said
disease or condition. In a more specific embodiment the invention
provides a compound of Formula (I) for use in the treatment or
prevention of a disease associated with LSD1. In another preferred
aspect, the therapeutically effective amount of a compound of
Formula (I) is an amount sufficient to modulate the level of
histone-3 lysine-4 methylation. In another preferred aspect, the
therapeutically effective amount of a compound of Formula (I) is an
amount sufficient to modulate the level of histone-3 lysine-9
methylation. In another preferred aspect, the therapeutically
effective amount of a compound of Formula (I) is an amount
sufficient to modulate the level gene expression.
[0263] In yet another aspect, the invention provides a
pharmaceutical composition comprising a compound of Formula (I) and
a pharmaceutically acceptable carrier. In a more specific aspect,
the pharmaceutical composition comprises a therapeutically
effective amount of a compound of Formula (I). In an even more
specific aspect, the therapeutically effective amount of a compound
of Formula (I) is an amount effective to inhibit LSD1. In another
preferred aspect, the therapeutically effective amount of a
compound of Formula (I) is an amount sufficient to modulate the
level of histone-3 lysine-4 methylation. In another preferred
aspect, the therapeutically effective amount of a compound of
Formula (I) is an amount sufficient to modulate the level of
histone-3 lysine-9 methylation. In another preferred aspect, the
therapeutically effective amount of a compound of Formula (I) is an
amount sufficient to modulate the level gene expression.
[0264] In again another aspect, the invention provides a method of
inhibiting LSD activity comprising administering, to a patient in
need of treatment, a therapeutically effective amount of a
composition comprising a compound of Formula (I) or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable carrier sufficient to inhibit LSD1 activity. This aspect
can be reformulated as a compound of Formula (I) as herein defined
for use as a LSD1 inhibitor. This aspect can also be reformulated
as the use of a compound of Formula (I) for the manufacture of a
medicament for the treatment or prevention of a disease associated
with LSD1. In a related aspect, a method for treating or preventing
an individual is provided, said method comprising identifying an
individual in need of treatment or prevention and administering to
said individual a therapeutically effective amount of a compound of
Formula (I). In a preferred aspect, the therapeutically effective
amount of a compound of Formula (I) is an amount sufficient to
inhibit LSD1. In another preferred aspect, the therapeutically
effective amount of a compound of Formula (I) is an amount
sufficient to modulate the level of histone-3 lysine-4 methylation.
In another preferred aspect, the therapeutically effective amount
of a compound of Formula (T) is an amount sufficient to modulate
the level of histone-3 lysine-9 methylation. In another preferred
aspect, the therapeutically effective amount of a compound of
Formula (I) is an amount sufficient to modulate the level gene
expression.
[0265] Preferred embodiments of the compounds of Formula (I) for
use in the composition and method of these aspects of the invention
are as defined herein above in the first aspect of the
invention.
[0266] In still another aspect, the invention provides a method of
treating or preventing cancer comprising administering, to a
patient in need of such treatment or prevention, a therapeutically
effective amount of a pharmaceutical composition comprising a
compound of Formula (I) as defined above in the first aspect of the
invention, and a pharmaceutically acceptable carrier. This aspect
can be reformulated as a compound of Formula (I) as defined above
for use in the treatment or prevention of cancer. In a related
aspect, the invention provides a pharmaceutical composition for use
in treating or preventing cancer wherein said composition comprises
a therapeutically effective amount of a compound of Formula (I)
sufficient for treating or preventing cancer. In another related
aspect, the invention provides a compound of Formula (I) or a
pharmaceutical composition for use in the treatment or prevention
of cancer, wherein said cancer is chosen from testicular cancer,
breast cancer, lung cancer, prostate cancer, colorectal cancer,
brain cancer, skin cancer, blood cancer (e.g., leukemia) and
lymphoma, wherein said composition comprises a therapeutically
effective amount of a compound of Formula (I) sufficient for
treating or preventing the said cancer. In a preferred aspect, the
therapeutically effective amount of a compound of Formula (I) is an
amount sufficient to inhibit LSD1. In another preferred aspect, the
therapeutically effective amount of a compound of Formula (I) is an
amount sufficient to modulate the level of histone 3 lysine 4
methylation. In another preferred aspect, the therapeutically
effective amount of a compound of Formula (I) is an amount
sufficient to the level of modulate histone 3 lysine 9 methylation.
In another preferred aspect, the therapeutically effective amount
of a compound of Formula (I) is an amount sufficient to modulate
the level gene expression.
[0267] In another preferred embodiment, a therapeutically effective
amount of the pharmaceutical composition is administered to an
individual in an amount sufficient to prevent or treat a disease.
In a more specific aspect, the disease is cancer. In an even more
specific aspect, the disease is a cancer chosen from prostate
cancer, testicular cancer, brain cancer, colorectal cancer, lung
cancer, breast cancer, skin cancer, and blood cancer.
[0268] Recent studies have implicated LSD1 in viral infection and
reactivation. In particular it was shown that pharmacological
inhibitors of LSD1 like parnate and siRNA knock down of LSD1 caused
reduced viral infectivity and reduced reactivation after latency
(Liang et al. (2009) Nat. Med. 15:1312-1317). Therefore it is
believed that the compounds of the invention can be used for
treating or preventing viral infection. Furthermore, it is believed
that the compounds of the invention can treat or prevent viral
reactivation after latency.
[0269] Thus, in another aspect, the invention provides a method for
treating or preventing a viral infection, the method comprising
administering to an individual (preferably a human) a compound of
Formula (I) as defined above in any of the aspects and embodiments
of the invention or a pharmaceutically acceptable salt or solvate
thereof. Accordingly, the invention also provides a compound of
Formula (I) as defined above in any of the aspects and embodiments
of the invention or a pharmaceutically acceptable salt or solvate
thereof for use in treating or preventing a viral infection. In one
specific embodiment, the viral infection is a herpesvirus
infection. In a more specific embodiment, the herpesvirus infection
is caused by and/or associated with a herpesvirus chosen from
HSV-1, HSV-2, and Epstein-Barr virus. In another embodiment of this
seventh aspect, the viral infection is caused by and/or associated
with HIV. In even more specific embodiment, the invention provides
a method for treating or preventing viral reactivation after
latency, the method comprising administering to an individual
(preferably a human) a compound of Formula (I) as defined above in
any of the aspects and embodiments of the invention or a
pharmaceutically acceptable salt or solvate thereof. Accordingly,
the invention also provides a compound of Formula (I) as defined
above in any of the aspects and embodiments of the invention or a
pharmaceutically acceptable salt or solvate thereof for use in
treating or preventing viral reactivation after latency. In a
specific embodiment, the virus that is reactivating is a
herpesvirus. In a more specific embodiment, the herpesvirus that is
reactivating is chosen from HSV-1, HSV-2, and Epstein-Barr virus.
In an even more specific embodiment, the virus that is reactivating
is HSV.
[0270] In one embodiment the invention provides a compound Formula
(I) or a pharmaceutically acceptable salt or solvate thereof,
wherein the compound is chosen from: [0271]
5-((trans)-2-aminocyclopropyl)-N-(3-chlorophenyl)pyridin-2-amine;
[0272]
5-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)pyridin-2-amine;
[0273]
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)phenyl)pyridin-2-ami-
ne; [0274]
5-((trans)-2-aminocyclopropyl)-N-(3-methoxyphenyl)pyridin-2-ami-
ne; [0275]
5-((trans)-2-aminocyclopropyl)-N-(4-methoxyphenyl)pyridin-2-ami-
ne; [0276] 5-((trans)-2-aminocyclopropyl)-N-p-tolylpyridin-2-amine;
[0277] 5-((trans)-2-aminocyclopropyl)-N-m-tolylpyridin-2-amine;
[0278]
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile;
[0279]
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile;
[0280]
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide;
[0281]
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide;
[0282]
5-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)pyridin-2-amine;
[0283]
5-((trans)-2-aminocyclopropyl)-N-(4-chlorobenzyl)pyridin-2-amine;
[0284]
5-((trans)-2-aminocyclopropyl)-N-(3-(trifluoromethyl)benzyl)pyridin-2-ami-
ne; [0285]
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)benzyl)pyr-
idin-2-amine; [0286]
5-((trans)-2-aminocyclopropyl)-N-(3-methylbenzyl)pyridin-2-amine;
[0287]
5-((trans)-2-aminocyclopropyl)-N-(4-methylbenzyl)pyridin-2-amine;
[0288]
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzonitrile;
[0289]
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzoni-
trile; [0290]
5-((trans)-2-aminocyclopropyl)-N-(3-methoxybenzyl)pyridin-2-amine;
[0291]
5-((trans)-2-aminocyclopropyl)-N-(4-methoxybenzyl)pyridin-2-amine;
[0292] 4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol;
[0293]
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzamide;
[0294]
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzami-
de; [0295]
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)phen-
ol; [0296]
5-((trans)-2-aminocyclopropyl)-N-(3-ethynylphenyl)pyridin-2-ami-
ne; [0297]
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indol-7-amine- ;
[0298]
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indazol-7-amine-
; or [0299]
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol.
[0300] In another embodiment the invention provides a compound
Formula (I) or a pharmaceutically acceptable salt or solvate
thereof, wherein the compound is chosen from: [0301]
5-((trans)-2-aminocyclopropyl)-N-(3-chlorophenyl)pyridin-2-amine;
[0302]
5-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)pyridin-2-amine;
[0303]
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)phenyl)pyridin-2-ami-
ne; [0304]
5-((trans)-2-aminocyclopropyl)-N-(3-methoxyphenyl)pyridin-2-ami-
ne; [0305]
5-((trans)-2-aminocyclopropyl)-N-(4-methoxyphenyl)pyridin-2-ami-
ne; [0306] 5-((trans)-2-aminocyclopropyl)-N-p-tolylpyridin-2-amine;
[0307] 5-((trans)-2-aminocyclopropyl)-N-m-tolylpyridin-2-amine;
[0308]
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile;
[0309]
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile;
[0310]
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide;
[0311]
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide;
[0312]
5-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)pyridin-2-amine;
[0313]
5-((trans)-2-aminocyclopropyl)-N-(4-chlorobenzyl)pyridin-2-amine;
[0314]
5-((trans)-2-aminocyclopropyl)-N-(3-(trifluoromethyl)benzyl)pyridin-2-ami-
ne; [0315]
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)benzyl)pyr-
idin-2-amine; [0316]
5-((trans)-2-aminocyclopropyl)-N-(3-methylbenzyl)pyridin-2-amine;
[0317]
5-((trans)-2-aminocyclopropyl)-N-(4-methylbenzyl)pyridin-2-amine;
[0318]
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzonitrile;
[0319]
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzoni-
trile; [0320]
5-((trans)-2-aminocyclopropyl)-N-(3-methoxybenzyl)pyridin-2-amine;
[0321]
5-((trans)-2-aminocyclopropyl)-N-(4-methoxybenzyl)pyridin-2-amine;
[0322] 4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol;
[0323]
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzamide;
[0324]
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzami-
de; [0325]
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)phen-
ol; [0326]
5-((trans)-2-aminocyclopropyl)-N-(3-ethynylphenyl)pyridin-2-ami-
ne; [0327]
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indol-7-amine- ;
[0328]
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indazol-7-amine-
; [0329] 3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol;
[0330] 4-((trans)-2-aminocyclopropyl)-N-(4-methylbenzyl)aniline;
[0331]
4-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)benzyl)aniline;
[0332] 4-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)aniline;
[0333]
3-(((4-((trans)-2-aminocyclopropyl)phenyl)amino)methyl)benzonitrile;
[0334] 4-((trans)-2-aminocyclopropyl)-N-(p-tolyl)aniline; [0335]
4-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)aniline; [0336]
3-((4-((trans)-2-aminocyclopropyl)phenyl)amino)benzonitrile; [0337]
N-(4-((trans)-2-aminocyclopropyl)phenyl)-3-methoxyaniline; or
[0338]
3-((4-((trans)-2-aminocyclopropyl)phenyl)amino)benzamide.
DEFINITIONS
[0339] Any definition herein may be used in combination with any
other definition to describe a composite structural group. By
convention, the trailing element of any such definition is that
which attaches to the parent moiety. For example, the composite
group alkylamido would represent an alkyl group attached to the
parent molecule through an amido group, and the term alkoxyalkyl
would represent an alkoxy group attached to the parent molecule
through an alkyl group.
[0340] As used herein, the term "acyl," refers to a carbonyl
attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl,
heterocyclyl, or any other moiety where the atom attached to the
carbonyl is carbon. An "acetyl" group refers to a
--C(.dbd.O)CH.sub.3 group. An "alkylcarbonyl" or "alkanoyl" group
refers to an alkyl group attached to the parent molecular moiety
through a carbonyl group. Examples of such groups include, but are
not limited to, methylcarbonyl or ethylcarbonyl. Examples of acyl
groups include, but are not limited to, formyl, alkanoyl or
aroyl.
[0341] As used herein, the term "acyloxy," refers to an acyl group
attached to the parent moiety through an oxygen atom.
[0342] As used herein, the term "alkenyl," refers to a
straight-chain or branched-chain hydrocarbon group having one or
more double bonds and containing from 2 to 20 carbon atoms. A
(C2-C6)alkenyl has from 2 to 6 carbon atoms. Examples of suitable
alkenyl groups include, but are not limited to, ethenyl, propenyl,
2-methylpropenyl, or 1,3-butadienyl.
[0343] As used herein, the term "alkenylene," refers to a
carbon-carbon double bond system attached at two or more positions
such as ethenylene e.g., --CH.dbd.CH--. Alkenylene groups include,
but are not limited to, (C2-C20)alkenylene groups, such as, e.g.,
ethenylene, propenylene, 2-methylpropenylene, or
1,3-butadienylene.
[0344] As used herein, the term "alkoxy," refers to an alkyl ether
group, wherein the term alkyl is as defined below. Examples of
suitable alkyl ether groups include, but are not limited to,
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy,
sec-butoxy, tert-butoxy, or n-pentoxy.
[0345] As used herein, the term "alkyl," refers to a straight-chain
or branched-chain alkyl group containing from 1 to 20 carbon atoms.
A (C1-C10)alkyl has from 1 to 10 carbon atoms and a (C1-C6)alkyl
has from 1 to 6 carbon atoms and a (C1-C4)alkyl has from 1 to 4
carbon atoms. Examples of alkyl groups include, but are not limited
to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, pentyl, isopentyl, neo-pentyl, iso-amyl,
hexyl, heptyl, octyl, or nonyl.
[0346] As used herein, the term "alkylene," refers to a saturated
aliphatic group derived from a straight or branched chain saturated
hydrocarbon attached at two or more positions. Alkylene groups
include, but are not limited to, (C1-C20)alkylene groups, such as,
e.g., methylene (--CH.sub.2--), ethylene (--CH.sub.2CH.sub.2--),
propylene (--CH.sub.2CH.sub.2CH.sub.2--) or isopropylene
(--CH(CH.sub.3)CH.sub.2--).
[0347] As used herein, the term "alkylamino," refers to an alkyl
group as defined herein which is attached to the parent molecular
moiety through an amino group. Suitable alkylamino groups may be
mono- or dialkylated. Exemplary alkylamino groups include, but are
not limited to, N-methylamino, N-ethylamino, N,N-dimethylamino,
N,N-ethylmethylamino, N,N-diethylamino, N-propylamino, or
N,N-methylpropylamino.
[0348] As used herein, the term "alkylidene," refers to an alkenyl
group in which one carbon atom of the carbon-carbon double bond
belongs to the moiety to which the alkenyl group is attached.
[0349] As used herein, the term "alkylthio," refers to an alkyl
thioether (R--S--) group wherein the term R is an alkyl is as
defined above wherein the group is attached to the parent molecule
through the sulfur group. Examples of suitable alkyl thioether
groups include, but are not limited to, methylthio, ethylthio,
n-propylthio, isopropylthio, n-butylthio, iso-butylthio,
sec-butylthio, or tert-butylthio.
[0350] As used herein, the term "alkynyl," refers to a
straight-chain or branched-chain hydrocarbon group having one or
more triple bonds and containing from 2 to 20 carbon atoms. A
(C2-C6)alkynyl has from 2 to 6 carbon atoms. A (C2-C4)alkynyl has
from 2 to 4 carbon atoms. Examples of alkynyl groups include, but
are not limited to, ethynyl, propynyl, butyn-1-yl, butyn-2-yl,
pentyn-1-yl, 3-methylbutyn-1-yl, or hexyn-2-yl.
[0351] As used herein, the term "alkynylene," refers to a
carbon-carbon triple bond attached at two positions such as
ethynylene (--C.dbd.C--). Alkynylene groups include, but are not
limited to, (C2-C20)alkynylene groups, such as, e.g., ethynylene or
propynylene,
[0352] As used herein, the terms "amido" and "carbamoyl," refer to
an amino group as described below attached to the parent molecular
moiety through a carbonyl group (e.g., --C(.dbd.O)NRR'), or vice
versa (--N(R)C(.dbd.O)NR'). "Amido" and "carbamoyl" encompass
"C-amido", "N-amido" and "acylamino" as defined herein. R and R'
are as defined herein.
[0353] As used herein, the term "C-amido," refers to a
--C(.dbd.O)NRR' group with R and R' as defined herein.
[0354] As used herein, the term "N-amido," refers to a
R'C(.dbd.O)NR-- group, with R and R' as defined herein.
[0355] As used herein, the term "acylamino," refers to an acyl
group attached to the parent moiety through an amino group. An
example of an "acylamino" group includes, but is not limited to,
acetylamino (CH.sub.3C(.dbd.O)NH--).
[0356] As used herein, the term "amino," refers to --NRR', wherein
R and R' are independently selected from the group consisting of
hydrogen, alkyl, heteroalkyl, aryl, carbocyclyl, and heterocyclyl.
Additionally, R and R' may be combined to form a heterocyclyl.
[0357] As used herein, the term "aryl," refers a carbocyclic
aromatic system containing one ring, or two or three rings fused
together where in the ring atoms are all carbon. The term "aryl"
groups includes, but is not limited to groups such as phenyl,
naphthyl, or anthracenyl.
[0358] As used herein, the term "arylalkenyl" or "aralkenyl,"
refers to an aryl group attached to the parent molecular moiety
through an alkenyl group.
[0359] As used herein, the term "arylalkoxy" or "aralkoxy," refers
to an aryl group attached to the parent molecular moiety through an
alkoxy group. Examples of arylalkoxy groups include, but are not
limited to, benzyloxy or phenethoxy.
[0360] As used herein, the term "arylalkyl" or "aralkyl," refers to
an aryl group attached to the parent molecular moiety through an
alkyl group.
[0361] As used herein, the term "arylalkynyl" or "aralkynyl,"
refers to an aryl group attached to the parent molecular moiety
through an alkynyl group.
[0362] As used herein, the term "arylalkanoyl" or "aralkanoyl" or
"aroyl," refers to an acyl group derived from an aryl-substituted
alkanecarboxylic acid including, but not limited to, benzoyl,
napthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl),
4-phenylbutyryl, (2-naphthyl)acetyl, or 4-chlorohydrocinnamoyl.
[0363] As used herein, the term "aryloxy," refers to an aryl group
attached to the parent molecular moiety through an oxy (--O--).
[0364] As used herein, the terms "benzo" and "benz," refer to the
divalent group C.sub.6H.sub.4=derived from benzene. Examples
include, but are not limited to, benzothiophene or
benzimidazole.
[0365] As used herein, the term "carbamate," refers to an
O-carbamyl or N-carbamyl group as defined herein.
[0366] As used herein, the term "O-carbamyl" refers to a
--OC(.dbd.O)NRR', group-with R and R' as defined herein.
[0367] As used herein, the term "N-carbamyl" refers to a
ROC(.dbd.O)NR'-- group, with R and R' as defined herein.
[0368] As used herein, the term "carbonyl," when alone includes
formyl --C(.dbd.O)H and in combination is a --C(.dbd.O)--
group.
[0369] As used herein, the term "carboxyl" or "carboxy" refers to
--C(.dbd.O)OH or the corresponding "carboxylate" anion, such as is
in a carboxylic acid salt. An "O-carboxy" group refers to a
RC(.dbd.O)O-- group, where R is as defined herein. A "C-carboxy"
group refers to a --C(.dbd.O)OR groups where R is as defined
herein.
[0370] As used herein, the term "cyano" refers to --CN.
[0371] As used herein, the term "carbocyclyl" refers to a saturated
or partially saturated monocyclic or a fused bicyclic or tricyclic
group wherein the ring atoms of the cyclic system are all carbon
and wherein each cyclic moiety contains from 3 to 12 carbon atom
ring members. "Carbocyclyl" encompasses benzo fused to a
carbocyclyl ring system. One group of carbocyclyls have from 5 to 7
carbon atoms. Examples of carbocyclyl groups include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and
cycloheptyl, tetrahydronapthyl, indanyl, octahydronaphthyl,
2,3-dihydro-1H-indenyl, or adamantyl.
[0372] As used herein, the term "cycloalkyl" refers to a saturated
monocyclic, bicyclic or tricyclic group wherein the ring atoms of
the cyclic system are all carbon and wherein each cyclic moiety
contains from 3 to 12 carbon atom ring members. One group of
cycloalkyls has from 5 to 7 carbon atoms. Examples of cycloalkyl
groups include, but are not limited to, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl.
[0373] As used herein, the term "cycloalkenyl" refers to a
partially saturated monocyclic, bicyclic or tricyclic group wherein
the ring atoms of the cyclic system are all carbon and wherein each
cyclic moiety contains from 3 to 12 carbon atom ring members. One
group of carboalkenyls have from 5 to 7 carbon atoms. Examples of
cycloalkenyl groups include, but are not limited to, cyclobutenyl,
cyclopentenyl, or cyclohexenyl.
[0374] As used herein, the term "cyclyl" refers to an aryl,
heterocyclyl, or carbocyclyl group as defined herein.
[0375] As used herein, the term "ester" refers to a carboxy group
bridging two moieties linked at carbon atoms.
[0376] As used herein, the term "ether" refers to an oxy group
bridging two moieties linked at carbon atoms.
[0377] As used herein, the term "halo" or "halogen" refers to
fluorine, chlorine, bromine, or iodine.
[0378] As used herein, the term "haloalkoxy" refers to a haloalkyl
group attached to the parent molecular moiety through an oxygen
atom. Examples of haloalkoxy groups include, but are not limited
to, trifluoromethoxy, 2-fluoroethoxy, or 3-chloropropoxy.
[0379] As used herein, the term "haloalkyl" refers to an alkyl
group having the meaning as defined above wherein one or more
hydrogens are replaced with a halogen. Specifically embraced are
monohaloalkyl, dihaloalkyl or polyhaloalkyl groups. A monohaloalkyl
group, for one example, may have an iodo, bromo, chloro or fluoro
atom within the group. Dihalo or polyhaloalkyl groups may have two
or more of the same halo atoms or a combination of different halo
groups. Examples of haloalkyl groups include, but are not limited
to, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,
dichloromethyl, trichloromethyl, pentafluoroethyl,
heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl,
difluoroethyl, difluoropropyl, dichloroethyl or dichloropropyl.
[0380] As used herein, "haloalkylene" refers to a haloalkyl group
attached at two or more positions. Examples include, but are not
limited to, fluoromethylene (--CFH--), difluoromethylene
(--CF.sub.2--), or chloromethylene (--CHCl--).
[0381] As used herein, the term "heteroalkyl" refers to a stable
straight or branched alkyl chain, wherein one, two, or three
carbons forming the alkyl chain are replaced by 1, 2, or 3
heteroatoms selected from the group consisting of O, N, and S, and
wherein the nitrogen and sulfur atoms may optionally be oxidized
and the nitrogen heteroatom may optionally be quaternized. The
heteroatom(s) O, N and S may be placed at any interior position of
the heteroalkyl group. Up to two heteroatoms may be consecutive,
such as, for example, --CH.sub.2--NH--OCH.sub.3.
[0382] As used herein, the term "heteroalkylene" refers to a
heteroalkyl group attached at two or more positions. Examples
include, but are not limited to, --CH.sub.2OCH.sub.2--,
--CH.sub.2SCH.sub.2--, --CH.sub.2NHCH.sub.2--, --CH.sub.2S--, or
--CH.sub.2NCH(CH.sub.3)CH.sub.2--.
[0383] As used herein, the term "heteroaryl," refers to a 3 to 7
membered unsaturated monocyclic ring, or a fused monocyclic,
bicyclic, or tricyclic ring system in which the rings are aromatic
and which at least one ring contains at least one atom selected
from the group consisting of O, S, and N. One group of heteroaryls
has from 5 to 7 carbon atoms. Examples of heteroaryl groups
include, but are not limited to, pyridinyl, imidazolyl,
imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl,
tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl,
oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl,
indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl,
indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl,
pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl,
thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl,
benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl,
naphthyridinyl, or furopyridinyl.
[0384] As used herein, the term "heterocyclyl" or "heterocycle,"
each refer to a saturated, partially unsaturated, or fully
unsaturated monocyclic, bicyclic, or tricyclic heterocyclic group
containing at least one heteroatom as a ring member, wherein each
said heteroatom may be independently selected from the group
consisting of nitrogen, oxygen, and sulfur wherein the nitron or
sulfur atoms may be oxidized (e.g., --N.dbd.O, --S(.dbd.O)--, or
--S(.dbd.O).sub.2--). Additionally, 1, 2, or 3 of the carbon atoms
of the heterocyclyl may be optionally oxidized (e.g., to give an
oxo group or .dbd.O). One group of heterocyclyls has from 1 to 4
heteroatoms as ring members. Another group of heterocyclyls has
from 1 to 2 heteroatoms as ring members. One group of heterocyclyls
has from 3 to 8 ring members in each ring. Yet another group of
heterocyclyls has from 3 to 7 ring members in each ring. Again
another group of heterocyclyls has from 5 to 6 ring members in each
ring. "Heterocyclyl" is intended to encompass a heterocyclyl group
fused to a carbocyclyl or benzo ring systems. Examples of
heterocyclyl groups include, but are not limited to, pyrrolidinyl,
tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl,
tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl,
piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl,
homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl,
oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl,
2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl,
dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl,
dihydropyranyl, dihydrothienyl, dihydrofuranyl,
pyrazolidinylimidazolinyl, or imidazolidinyl. Examples of
heteroaryls that are heterocyclyls include, but are not limited to,
pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl,
triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl,
thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl,
quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,
cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl,
triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl,
thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl,
benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl,
quinoxalinyl, naphthyridinyl, or furopyridinyl.
[0385] As used herein, the term "heterocycloalkyl," refers to a
heterocyclyl group that is not fully saturated e.g., one or more of
the rings systems of a heterocycloalkyl is not aromatic. Examples
of heterocycloalkyls include piperazinyl, morpholinyl, piperidinyl,
or pyrrolidinyl.
[0386] As used herein, the term "hydroxyl," as used herein, refers
to --OH.
[0387] As used herein, the term "hydroxyalkyl," as used herein,
refers to a hydroxy group attached to the parent molecular moiety
through an alkyl group.
[0388] As used herein, the phrase "in the main chain," refers to
the longest contiguous or adjacent chain of carbon atoms starting
at the point of attachment of a group to the compounds of any one
of the formulas disclosed herein.
[0389] As used herein, the term "isocyanato," refers to a
--N.dbd.C.dbd.O group.
[0390] As used herein, the term "isothiocyanato," refers to a
--N.dbd.C.dbd.S group.
[0391] As used herein, the term phrase "linear chain of atoms"
refers to the longest straight chain of atoms independently
selected from carbon, nitrogen, oxygen and sulfur.
[0392] As used herein, the term "lower," where not otherwise
specifically defined, means containing from 1 to and including 6
carbon atoms.
[0393] As used herein, the term "lower alkynyl" refers to a
straight-chain or branched-chain hydrocarbon group having one or
more triple bonds and containing from 2 to 6 carbon atoms.
[0394] Examples of lower alkynyl groups include, but are not
limited to, ethynyl, propynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl,
3-methylbutyn-1-yl, or hexyn-2-yl.
[0395] As used herein, the term "lower aryl," means phenyl or
naphthyl.
[0396] As used herein, the term "lower heteroaryl," means
monocyclic heteroaryl comprising five or six ring members, of which
between one and four of said ring members may be heteroatoms
selected from O, S, or N.
[0397] As used herein, the term "lower cycloalkyl," refers to a
monocyclic cycloalkyl having between three and six ring members.
Examples of lower cycloalkyl include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0398] As used herein, the term "lower carbocyclyl" refers to a
saturated or partially saturated monocyclic group, the ring atoms
of which are all carbon atoms, wherein said monocyclic group
contains from 3 to 6 carbon atom ring members. Examples of lower
carbocyclyl groups include, but are not limited to, cyclopropyl,
cyclobutyl, cyclopentyl, or cyclohexyl.
[0399] As used herein, the term "lower heterocyclyl," refers to a
monocyclic heterocyclyls having between three and six ring members,
of which between one and four may be heteroatoms selected from the
group consisting of O, S, and N wherein the N and S group may be
optionally oxidized (e.g., --N(.dbd.O)--, --S(.dbd.O)--, and
--S(.dbd.O).sub.2--)). Examples of lower heterocyclyls include, but
are not limited to, pyrrolidinyl, imidazolidinyl, pyrazolidinyl,
piperidinyl, piperazinyl, and morpholinyl. Lower heterocyclyls may
be saturated or partially unsaturated which is a lower
heterocycloalkyl.
[0400] As used herein, the term "lower amino," refers to --NRR',
wherein R and R' are independently selected from the group
consisting of hydrogen, lower alkyl, and lower heteroalkyl.
Additionally, the R and R' of a lower amino group may combine to
form a five- or six-membered heterocycloalkyl.
[0401] As used herein, the term "mercaptyl," refers to an RS--
group, where R is as defined herein.
[0402] As used herein, the term "nitro," refers to --NO.sub.2.
[0403] As used herein, the terms "oxy" or "oxa," refer to
--O--.
[0404] As used herein, the term "oxo," refers to .dbd.O.
[0405] As used herein, the terms "sulfonate" "sulfonic acid" and
"sulfonic," refers to the --SO.sub.3H group and its anion as the
sulfonic acid is used in salt formation.
[0406] As used herein, the term "sulfanyl," to --S--.
[0407] As used herein, the term "sulfinyl," refers to
--S(.dbd.OXR)--, with R as defined herein.
[0408] As used herein, the term "sulfonyl," refers to
--S(.dbd.O).sub.2R, with R as defined herein.
[0409] As used herein, the term "sulfonamide", refers to an
N-sulfonamido or S-sulfonamido group as defined herein.
[0410] As used herein, the term "N-sulfonamido," refers to a
RS(.dbd.O).sub.2N(R')-- group with R and R' as defined herein.
[0411] As used herein, the term "S-sulfonamido," refers to a
--S(O).sub.2NRR', group, with R and R' as defined herein.
[0412] As used herein, the terms "thia" and "thio," refer to a
--S-- group or another wherein the oxygen is replaced with sulfur.
The oxidized derivatives of the thio group, namely sulfinyl and
sulfonyl, are included in the definition of thia and thio.
[0413] As used herein, the term "thiol," refers to an --SH
group.
[0414] As used herein, the term "thiocarbonyl," when alone includes
thioformyl --C(.dbd.S)R group with R as defined herein.
[0415] As used herein, the term "N-thiocarbamyl," refers to an
ROC(.dbd.S)N(R')-- group, with R and R' as defined herein.
[0416] As used herein, the term "O-thiocarbamyl," refers to a
--OC(.dbd.S)NRR' group with R and R' as defined herein.
[0417] As used herein, the term "thiocyanato," refers to a --SCN
group.
[0418] As used herein, the term "trihalomethanesulfonamido," refers
to a X.sub.3CS(.dbd.O).sub.2N(R)-- group where X is an
independently chosen halogen and R as defined herein.
[0419] As used herein, the term "trihalomethanesulfonyl," refers to
a X.sub.3CS(O).sub.2-- group where X is an independently chosen
halogen.
[0420] As used herein, the term "trihalomethoxy," refers to a
X.sub.3CO-- group where X is an independently chosen halogen.
[0421] As used herein, the term "trisubstituted silyl," refers to a
silicone group substituted at its three free valences with groups
as listed herein under the definition of for R and R'. Examples
include, but are not limited to, trimethysilyl,
tert-butyldimethylsilyl, or triphenylsilyl.
[0422] As used herein, the term "urea," refers to a
--N(R)C(.dbd.O)N(R') group wherein R and R' are as defined
herein.
[0423] As used herein, the term "optionally substituted" means the
preceding or anteceding group may be substituted or unsubstituted.
When substituted, the substituents of an "optionally substituted"
group may include, without limitation and unless defined otherwise,
one or more substituents independently selected from the following
groups or a particular designated set of groups, alone or in
combination: lower alkyl, lower alkenyl, lower alkynyl, lower
alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower
haloalkyl, lower haloalkenyl, lower haloalkynyl, lower
perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl,
aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy,
carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower
carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower
alkylamino, arylamino, aminoalkyl, amido, nitro, thiol, lower
alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio,
sulfonate, sulfonic acid, trisubstituted silyl, N.sub.3, SH,
SCH.sub.3, C(O)CH.sub.3, CO.sub.2CH.sub.3, CO.sub.2H, pyridinyl,
thiophene, furanyl, carbamate, and urea. Two substituents may be
joined together to form a fused five-, six-, or seven-membered
carbocyclic or heterocyclic ring consisting of zero to three
heteroatoms, for example forming methylenedioxy or ethylenedioxy.
An optionally substituted group may be unsubstituted (e.g.,
--CH.sub.2CH.sub.3), fully substituted (e.g., --CF.sub.2CF.sub.3),
monosubstituted (e.g., --CH.sub.2CH.sub.2F) or substituted at a
level anywhere in-between fully substituted and monosubstituted
(e.g., --CH.sub.2CF.sub.3). Where substituents are recited without
qualification as to substitution, both substituted and
unsubstituted forms are encompassed. Where a substituent is
qualified as "substituted," the substituted form is specifically
intended. Additionally, different sets of optional substituents to
a particular moiety may be defined as needed; in these cases, the
optional substitution will be as defined, often immediately
following the phrase, "optionally substituted with." In one
specific definition, the optional substituents are chosen from
hydroxyl, halo, alkyl, alkoxy, haloalkyl, haloalkoxy,
--N((C1-C3)alkyl).sub.2, --NH((C1-C3)alkyl),
--NHC(.dbd.OX(C1-C3)alkyl), --C(.dbd.O)OH,
--C(.dbd.O)O((C1-C3)alkyl), --C(.dbd.O)(C1-C3)alkyl),
--C(.dbd.O)NH.sub.2, --C(.dbd.O)NH(C1-C3)alkyl),
--C(.dbd.O)NH(cycloalkyl), --C(.dbd.O)N(C1-C3)alkyl).sub.2,
--S(.dbd.O).sub.2((C1-C3)alkyl), --S(.dbd.O).sub.2NH.sub.2,
--S(.dbd.O).sub.2N((C1-C3)alkyl).sub.2,
--S(.dbd.O).sub.2NH((C1-C3)alkyl), --CHF.sub.2, --OCF.sub.3,
--OCHF.sub.2, --SCF.sub.3, --CF.sub.3, --CN, --NH.sub.2,
--NO.sub.2, or tetrazolyl.
[0424] The term R or the term R', appearing by itself and without a
number designation, unless otherwise defined, refers to a moiety
selected from the group consisting of hydrogen, alkyl, cycloalkyl,
heteroalkyl, haloalkyl, aryl, heteroaryl and heterocycloalkyl.
Whether an R group has a number designation or not, every R group,
including R, R' and R.sup.P where p=(1, 2, 3, . . . p), every
substituent, and every term should be understood to be independent
of every other in terms of selection from a group. Should any
variable, substituent, or term (e.g., aryl, heterocyclyl, R, etc.)
occur more than one time in a formula or generic structure, its
definition at each occurrence is independent of the definition at
every other occurrence. Those of skill in the art will further
recognize that certain groups may be attached to a parent molecule
or may occupy a position in a chain of elements from either end as
written. Thus, by way of example only, an unsymmetrical group such
as --C(.dbd.O)N(R)-- may be attached to the parent moiety at either
the carbon or the nitrogen.
[0425] Asymmetric centers exist in the compounds disclosed herein.
These centers are designated by the symbols "R" or "S," depending
on the configuration of substituents around the chiral carbon atom.
It should be understood that the invention encompasses all
stereochemical isomeric forms, including diastereomeric,
enantiomeric, and epimeric forms, as well as d-isomers and
l-isomers, and mixtures thereof. Individual stereoisomers of
compounds can be prepared synthetically from commercially available
starting materials which contain chiral centers or by preparation
of mixtures of enantiomeric products followed by separation such as
conversion to a mixture of diastereomers followed by separation or
recrystallization, chromatographic techniques, direct separation of
enantiomers on chiral chromatographic columns, or any other
appropriate method known in the art. Starting compounds of
particular stereochemistry are either commercially available or can
be made and resolved by techniques known in the art. Additionally,
the compounds disclosed herein may exist as geometric isomers. The
present invention includes all cis, trans, syn, anti, entgegen (E),
and zusammen (Z) isomers as well as the appropriate mixtures
thereof. Additionally, compounds may exist as tautomers; all
tautomeric isomers are provided by this invention. Additionally,
the compounds disclosed herein can exist in unsolvated as well as
solvated forms with pharmaceutically acceptable solvents such as
water, ethanol, and the like. In general, the solvated forms are
considered equivalent to the unsolvated forms. The compounds of
formula I may exist in different physical forms, i.e. amorphous and
crystalline forms. Moreover, the compounds of the invention may
have the ability to crystallize in more than one form, a
characteristic which is known as polymorphism. Polymorphs can be
distinguished by various physical properties well known in the art
such as X-ray diffraction pattern, melting point or solubility. All
physical forms of the compounds of formula I, including all
polymorphic forms ("polymorphs") thereof, are included within the
scope of the invention.
[0426] As used herein, the term "preventing an increase in a
symptom," refers to both not allowing a symptom to increase or
worsen, as well as reducing the rate of increase in the symptom.
For example, a symptom can be measured as the amount of particular
disease marker, i.e., a protein (e.g., cancer biomarker). In
another example the symptom can be cognitive decline. Preventing an
increase, according to the definition provided herein, means that
the amount of symptom (e.g., protein or cognitive decline) does not
increase or that the rate at which it increases is reduced.
[0427] As used herein, the term "treating a disease or disorder,"
refers to a slowing of or a reversal of the progress of the
disease. Treating a disease or disorder includes treating a symptom
and/or reducing the symptoms of the disease.
[0428] As used herein, the term "preventing a disease or disorder,"
refers to a slowing of the disease or of the onset of the disease
or the symptoms thereof. Preventing a disease or disorder can
include stopping the onset of the disease or symptoms thereof. As
used herein, the term "unit dosage form" refers to a physically
discrete unit, such as a capsule or tablet suitable as a unitary
dosage for a human patient. Each unit contains a predetermined
quantity of a compound of Formula (I), which was discovered or
believed to produce the desired pharmacokinetic profile which
yields the desired therapeutic effect. The dosage unit is composed
of a compound of Formula (I), in association with at least one
pharmaceutically acceptable carrier, salt, excipient, or
combination thereof.
[0429] As used herein, the term "subject" or "patient" or
"individual", such as the subject in need of treatment or
prevention, refers to, e.g., a eukaryote, an animal, a vertebrate
animal, a mammal, a rodent (e.g. a guinea pig, a hamster, a rat, a
mouse), a murine (e.g. a mouse), a canine (e.g. a dog), a feline
(e.g. a cat), an equine (e.g. a horse), a primate, a simian (e.g. a
monkey or ape), a monkey (e.g. a marmoset, a baboon), an ape (e.g.
gorilla, chimpanzee, orangutang, gibbon), or a human. The meaning
of the terms "eukaryote", "animal", "mammal", etc. is well known in
the art and can, for example, be deduced from Wehner und Gehring
(1995; Thieme Verlag). In the context of this invention, it is
particularly envisaged that animals are to be treated which are
economically, agronomically or scientifically important.
Scientifically important organisms include, but are not limited to,
mice, rats, and rabbits. Lower organisms such as, e.g., fruit flies
like Drosophila melagonaster and nematodes like Caenorhabditis
elegans may also be used in scientific approaches. Non-limiting
examples of agronomically important animals are sheep, cattle and
pig, while, for example, cats and dogs may be considered as
economically important animals. Preferably, the subject/patient is
a mammal; more preferably, the subject/patient is a human or a
non-human mammal (such as, e.g., a guinea pig, a hamster, a rat, a
mouse, a rabbit, a dog, a cat, a horse, a monkey, an ape, a
marmoset, a baboon, a gorilla, a chimpanzee, an orangutang, a
gibbon, a sheep, cattle, or a pig); even more preferably, the
subject/patient is a human.
[0430] As used herein, the term "dose" or "dosage," refers the
amount of active ingredient that an individual takes or is
administered at one time. For example, a 40 mg dose of a compound
of Formula (I) refers to, in the case of a twice-daily dosage
regimen, a situation where the individual takes 40 mg of a compound
of Formula (I) twice a day, e.g., 40 mg in the morning and 40 mg in
the evening. The 40 mg of a compound of Formula (I) dose can be
divided into two or more dosage units, e.g., two 20 mg dosage units
of a compound of Formula (I) in tablet form or two 20 mg dosage
units of a compound of Formula (I) in capsule form.
[0431] As used herein, a "pharmaceutically acceptable prodrug" is a
compound that may be converted under physiological conditions or by
solvolysis to the specified compound or to a pharmaceutically
acceptable salt of such compound.
[0432] As used herein, a "pharmaceutically active metabolite" is
intended to mean a pharmacologically active product produced
through metabolism in the body of a specified compound or salt
thereof. Metabolites of a compound may be identified using routine
techniques known in the art and their activities determined using
tests such as those described herein.
[0433] As used herein, a "pharmaceutically acceptable salt" is
intended to mean a salt that retains the biological effectiveness
of the free acids and bases of the specified compound and that is
not biologically or otherwise undesirable. A compound for use in
the invention may possess a sufficiently acidic, a sufficiently
basic, or both functional groups, and accordingly react with any of
a number of inorganic or organic bases, and inorganic and organic
acids, to form a pharmaceutically acceptable salt. Exemplary
pharmaceutically acceptable salts include those salts prepared by
reaction of the compounds of the present invention with a mineral
or organic acid or an inorganic base, such as salts including
sulfates, pyrosulfates, bisulfates, sulfites, bisulfites,
phosphates, monohydrophosphates, dihydrophosphates, metaphosphates,
pyrophosphates, chlorides, bromides, iodides, acetates,
propionates, decanoates, caprylates, acrylates, formates,
isobutyrates, caproates, heptanoates, propiolates, oxalates,
malonates, succinates, suberates, sebacates, fumarates, maleates,
butyne-1,4 dioates, hexyne-1,6-dioates, benzoatcs, chlorobenzoates,
methylbenzoates, dinitrobenzoates, hydroxybenzoates,
methoxybenzoates, phthalates, sulfonates, xylenesulfonates,
phenylacetates, phenylpropionates, phenylbutyrates, citrates,
lactates, gamma-hydroxybutyrates, glycollates, tartrates,
methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates,
naphthalene-2-sulfonates, or mandelates.
[0434] As used herein, a "pharmaceutically acceptable carrier"
refers to a non-API (API refers to Active Pharmaceutical
Ingredient) substances such as disintegrators, binders, fillers,
and lubricants used in formulating pharmaceutical products. They
are generally safe for administering to humans according to
established governmental standards, including those promulgated by
the United States Food and Drug Administration and the European
Medical Agency.
[0435] As is understood by the skilled artisan, certain variables
in the list of substituents are repetitive (different name for the
same substituent), generic to other terms in the list, and/or
partially overlap in content with other terms. In the compounds of
the invention, the skilled artisan recognizes that substituents may
be attached to the remainder of the molecule via a number of
positions and the preferred positions are as illustrated in the
Examples.
[0436] Additionally, the compound of Formula (I) can contain
asymmetric carbon atoms and can therefore exist in racemic and
optically active forms. Thus, optical isomers or enantiomers,
racemates, tautomers, and diastereomers are also encompassed in the
compounds of Formula (I). The methods of present invention include
the use of all such isomers and mixtures thereof. Methods of
separation of enantiomeric and diastercomeric mixtures are well
known to one skilled in the art. For example, racemic forms can be
resolved by physical methods, such as, e.g., fractional
crystallization, separation or crystallization of diastereomeric
derivatives or separation by chiral column chromatography. The
individual optical isomers can be obtained from the racemates using
conventional methods, such as, e.g., salt formation with an
optically active acid followed by crystallization. The present
invention encompasses any isolated racemic or optically active form
of compounds described in Formula (I), or any mixture thereof. In
one aspect, the compounds of the invention have a trans
configuration around the cyclopropyl ring as in
trans-phenylcyclopropylamine. In one aspect, the compounds of the
invention have a cis configuration around the cyclopropyl ring as
in cis-phenylcyclopropylamine. In a preferred aspect, the compounds
of Formula (I) have the trans configuration.
[0437] Typically, compounds according to Formula (I) can be
effective at an amount of from about 0.01 .mu.g/kg to about 100
mg/kg per day based on total body weight. The active ingredient may
be administered at once, or may be divided into a number of smaller
doses to be administered at predetermined intervals of time. The
suitable dosage unit for each administration can be, e.g., from
about 1 .mu.g to about 2000 mg, preferably from about 5 .mu.g to
about 1000 mg.
[0438] It should be understood that the dosage ranges set forth
above are exemplary only and are not intended to limit the scope of
this invention. The therapeutically effective amount for each
active compound can vary with factors including but not limited to
the activity of the compound used, stability of the active compound
in the patient's body, the severity of the conditions to be
alleviated, the total weight of the patient treated, the route of
administration, the ease of absorption, distribution, and excretion
of the active compound by the body, the age and sensitivity of the
patient to be treated, and the like, as will be apparent to a
skilled artisan. The amount of administration can be adjusted as
the various factors change over time.
[0439] For oral delivery, the active compounds can be incorporated
into a formulation that includes pharmaceutically acceptable
carriers such as binders (e.g., gelatin, cellulose, gum
tragacanth), excipients (e.g., starch, lactose), lubricants (e.g.,
magnesium stearate, silicon dioxide), disintegrating agents (e.g.,
alginate, Primogel, and corn starch), and sweetening or flavoring
agents (e.g., glucose, sucrose, saccharin, methyl salicylate, and
peppermint). The formulation can be orally delivered in the form of
enclosed gelatin capsules or compressed tablets. Capsules and
tablets can be prepared in any conventional techniques. The
capsules and tablets can also be coated with various coatings known
in the art to modify the flavors, tastes, colors, and shapes of the
capsules and tablets. In addition, liquid carriers such as fatty
oil can also be included in capsules.
[0440] Suitable oral formulations can also be in the form of
suspension, syrup, chewing gum, wafer, elixir, and the like. If
desired, conventional agents for modifying flavors, tastes, colors,
and shapes of the special forms can also be included. In addition,
for convenient administration by enteral feeding tube in patients
unable to swallow, the active compounds can be dissolved in an
acceptable lipophilic vegetable oil vehicle such as olive oil, corn
oil and safflower oil.
[0441] The active compounds can also be administered parenterally
in the form of solution or suspension, or in lyophilized form
capable of conversion into a solution or suspension form before
use. In such formulations, diluents or pharmaceutically acceptable
carriers such as sterile water and physiological saline buffer can
be used. Other conventional solvents, pH buffers, stabilizers,
anti-bacteria agents, surfactants, and antioxidants can all be
included. For example, useful components include sodium chloride,
acetates, citrates or phosphates buffers, glycerin, dextrose, fixed
oils, methyl parabens, polyethylene glycol, propylene glycol,
sodium bisulfate, benzyl alcohol, ascorbic acid, and the like. The
parenteral formulations can be stored in any conventional
containers such as vials and ampoules.
[0442] Routes of topical administration include nasal, bucal,
mucosal, rectal, or vaginal applications. For topical
administration, the active compounds can be formulated into
lotions, creams, ointments, gels, powders, pastes, sprays,
suspensions, drops and aerosols. Thus, one or more thickening
agents, humectants, and stabilizing agents can be included in the
formulations. Examples of such agents include, but are not limited
to, polyethylene glycol, sorbitol, xanthan gum, petrolatum,
beeswax, or mineral oil, lanolin, squalene, and the like. A special
form of topical administration is delivery by a transdermal patch.
Methods for preparing transdermal patches are disclosed, e.g., in
Brown, et al. (1988) Ann. Rev. Med. 39:221-229 which is
incorporated herein by reference.
[0443] Subcutaneous implantation for sustained release of the
active compounds may also be a suitable route of administration.
This entails surgical procedures for implanting an active compound
in any suitable formulation into a subcutaneous space, e.g.,
beneath the anterior abdominal wall. See, e.g., Wilson et al.
(1984) J. Clin. Psych. 45:242-247. Hydrogels can be used as a
carrier for the sustained release of the active compounds.
Hydrogels are generally known in the art. They are typically made
by crosslinking high molecular weight biocompatible polymers into a
network, which swells in water to form a gel like material.
Preferably, hydrogels are biodegradable or biosorbable. For
purposes of this invention, hydrogels made of polyethylene glycols,
collagen, or poly(glycolic-co-L-lactic acid) may be useful. See,
e.g., Phillips et al. (1984) J. Pharmaceut. Sci., 73:
1718-1720.
[0444] The active compounds can also be conjugated, to a water
soluble non-immunogenic non-peptidic high molecular weight polymer
to form a polymer conjugate. For example, an active compound is
covalently linked to polyethylene glycol to form a conjugate.
Typically, such a conjugate exhibits improved solubility,
stability, and reduced toxicity and immunogenicity. Thus, when
administered to a patient, the active compound in the conjugate can
have a longer half-life in the body, and exhibit better efficacy.
See generally, Burnham (1994) Am. J. Hosp. Pharm. 15:210-218.
PEGylated proteins are currently being used in protein replacement
therapies and for other therapeutic uses. For example, PEGylated
interferon (PEG-INTRON A.RTM.) is clinically used for treating
Hepatitis B. PEGylated adenosine deaminase (ADAGEN.RTM.) is being
used to treat severe combined immunodeficiency disease (SCIDS).
PEGylated L-asparaginase (ONCAPSPAR.RTM.) is being used to treat
acute lymphoblastic leukemia (ALL). It is preferred that the
covalent linkage between the polymer and the active compound and/or
the polymer itself is hydrolytically degradable under physiological
conditions. Such conjugates known as "prodrugs" can readily release
the active compound inside the body. Controlled release of an
active compound can also be achieved by incorporating the active
ingredient into microcapsules, nanocapsules, or hydrogels generally
known in the art. Other pharmaceutically acceptable prodrugs of the
compounds of this invention include, but are not limited to,
esters, carbonates, thiocarbonates, N-acyl derivatives,
N-acyloxyalkyl derivatives, quaternary derivatives of tertiary
amines, N-Mannich bases, Schiff bases, amino acid conjugates,
phosphate esters, metal salts and sulfonate esters.
[0445] Liposomes can also be used as carriers for the active
compounds of the present invention. Liposomes are micelles made of
various lipids such as cholesterol, phospholipids, fatty acids, and
derivatives thereof. Various modified lipids can also be used.
Liposomes can reduce the toxicity of the active compounds, and
increase their stability. Methods for preparing liposomal
suspensions containing active ingredients therein are generally
known in the art. See, e.g., U.S. Pat. No. 4,522,811; Prescott,
Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York,
N. Y. (1976).
[0446] The active compounds can also be administered in combination
with another active agent that synergistically treats or prevents
the same symptoms or is effective for another disease or symptom in
the patient treated so long as the other active agent does not
interfere with or adversely affect the effects of the active
compounds of this invention. Such other active agents include but
are not limited to anti-inflammation agents, antiviral agents,
antibiotics, antifungal agents, antithrombotic agents,
cardiovascular drugs, cholesterol lowering agents, anti-cancer
drugs, hypertension drugs, and the like.
[0447] Examples of antineoplastic agents that can be used in
combination with the compounds and methods of the present invention
include, in general, and as appropriate, alkylating agents,
anti-metabolites, epidophyllotoxins, antineoplastic enzymes,
topoisomerase inhibitors, procarbazines, mitoxantrones, platinum
coordination complexes, biological response modifiers and growth
inhibitors, hormonal/anti-hormonal therapeutic agents and
haematopoietic growth factors. Exemplary classes of antineoplastic
include the anthracyclines, vinca drugs, mitomycins, bleomycins,
cytotoxic nucleosides, epothilones, discodermolides, pteridines,
diynenes and podophyllotoxins. Particularly useful members of those
classes include, for example, carminomycin, daunorubicin,
aminopterin, methotrexate, methopterin, dichloromethotrexate,
mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine,
gemcitabine, cytosine arabinoside, podophyllotoxin or
podo-phyllotoxin derivatives such as etoposide, etoposide phosphate
or teniposide, melphalan, vinblastine, vincristine, leurosidine,
vindesine, leurosine, paclitaxel and the like. Other useful
antineoplastic agents include estramustine, carboplatin,
cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan,
hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate,
dacarbazine, L-asparaginase, camptothecin, CPT-1, topotecan, ara-C,
bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives,
interferons and interleukins.
General Synthetic Route Description
[0448] The compounds of formula (I) can be obtained by following
the processes described below. As it will be obvious to one skilled
in the art, the exact method used to prepare a given compound may
vary depending on its chemical structure. Unless otherwise stated,
in the methods described below the meanings of the different
substituents are the meanings described above with regard to a
compound of formula (I).
[0449] The compounds of Formula (I) can be synthesized, for
example, by the general route described in the Scheme 1:
##STR00005##
[0450] Aldehydes of Formula (1) are subjected to a
Horner-Wadsworth-Emmons reaction under standard conditions, well
known in the art, such as using triethyl phosphono acetate and a
strong base preferably potassium tert-butoxide in a suitable
solvent such as tetrahydrofurane at a suitable temperature
preferably around 0.degree. C. to get the ethyl acrylate
derivatives of formula (2), which are then subjected to
cyclopropanation reaction using trimethylsulfoxonium iodide and
sodium hydride in dimethyl sulfoxide as a solvent at a suitable
temperature, preferably around room temperature, leading to
(trans)-ethyl cyclopropanecarboxylate derivatives of formula (3)
(as a racemic mixture of the (1S,2R) and (1R,2S) isomers).
Hydrolysis to the corresponding (trans)-cyclopropanecarboxylic acid
derivatives of formula (4) can be performed under basic conditions
using for example NaOH in a suitable solvent such as MeOH at room
temperature. The subsequent reaction of compound (4), first with
ethyl chloroformate and triethylamine in acetone at low
temperature, e.g. -15.degree. C., and later with sodium azide in
water at low temperature, e.g. -10.degree. C., leads to the
formation of (trans)-cyclopropanecarbonyl azide derivatives of
formula (5). Reaction with tert-butanol results in the formation of
tert-butyl (trans)-cyclopropylcarbamate derivatives of formula (6).
The reaction of compound (6) with amine derivatives of formula (7)
using Xantphos, Tris(dibenzylideneacetone)dipalladium(0) as
catalyst, and a base such as sodium tert-butoxide in a suitable
solvent such as dioxane at a suitable temperature such as for
example around 80.degree. C. leads to the formation of tert-butyl
(trans)-cyclopropylcarbamate derivatives of formula (8).
Deprotection of the Boc-group in acidic conditions, for example
using HCl 2M in diethyl ether or dioxane in a suitable solvent such
as diethyl ether or dioxane, respectively, leads to the formation
of the (trans)-cyclopropanamine derivatives of formula (9), which
correspond to a compound of the present invention as defined
above.
[0451] Individual isomers (1S, 2R) and (1R, 2S) can be obtained by
chiral separation of the trans racemic mixture of compounds (9)
thus obtained. Alternatively, the separation of the trans racemic
mixture into the individual trans (1S, 2R) and (1R, 2S) isomers can
be performed upon the intermediate (3) and then the above synthetic
pathway from compound (3) onwards is performed using the single
(1S, 2R) or (1R, 2S) isomers of (3) to render directly the (1S,2R)
or (1R,2S) isomers of compound (9), respectively.
[0452] Aldehydes of formula (1) and amines of formula (7) are
commercially available or can be prepared using well known
synthetic procedures starting from readily available starting
materials.
[0453] The compounds of Formula (I) can also be prepared in
accordance with the following exemplary method described in Scheme
2:
##STR00006##
[0454] Commercially available aldehydes of Formula (I) have been
subjected to a Horner-Wadsworth-Emmons reaction using triethyl
phosphono acetate and potassium tert-butoxide in tetrahydrofurane
at 0.degree. C. to get the ethyl acrylate derivatives of formula
(2) which is subjected to cyclopropanation reaction using
trimethylsulfoxonium iodide and sodium hydride in dimethyl
sulfoxide as a solvent leading to (trans)-ethyl
cyclopropanecarboxylate derivatives of formula (3) (being trans
((1S, 2R), (1R,2S)) mixture although the individual
diastereoisomers corresponding to (1S, 2R) and (1R, 2S) can be
used). Hydrolysis to the corresponding
(trans)-cyclopropanecarboxylic acid derivatives of formula (4) was
performed using NaOH in MeOH. The reaction, first with ethyl
chloroformate and triethylamine in acetone and later with sodium
azide in water leads to the formation of
(trans)-cyclopropanecarbonyl azide derivatives of formula (5).
Reaction with tert-butanol results in the formation of tert-butyl
(trans)-cyclopropylcarbamate derivatives of formula (6). Their
reaction with commercially available amine derivatives of formula
(7) using Xantphos, Tris(dibenzylideneacetone)dipalladium(0) as a
catalyst, sodium tert-butoxide as a base and dioxane as a solvent
leads to the formation of tert-butyl (trans)-cyclopropylcarbamate
derivatives of formula (8). Deprotection of the Boc-group using HCl
2M in diethyl ether using diethyl ether as a solvent leads to the
formation of the corresponding hydrochloride salt of the
(trans)-cyclopropanamine derivatives of formula (9), which are
subject of the present invention as defined above.
[0455] The compounds of Formula (I), in which E is --N(R3)-, --S--
or --O--, can be prepared in accordance with the synthetic route
described in Scheme 2 above, using commercially available,
five-membered ring reagents (particularly five-membered ring
aldehydes), such as, e.g., suitably substituted thiophene
derivatives, thiazole derivatives, etc., as starting materials.
EXAMPLES
[0456] The program used to generate the names corresponding to the
structures in the Example compounds below was ChemBioDraw Ultra
11.0.1. This program named the molecules as the (1S,2R)
configuration due to the configuration of the input structure and
the "trans" term has been substituted in the place of the (1S,2R)
term specified by the program. The structures depicted for the
Example compounds below are shown as having one particular
stereochemical configuration around the cyclopropyl carbon atoms of
the cyclylcyclopropylamine (e.g., phenylcyclopropylamine) core (1S,
2R). All the compounds synthesized in the Examples are mixtures
having both configurations (1R,2S) and (1S,2R), that is to say they
are "trans" in respect to the cyclopropyl ring of the cyclopropyl
ring system. This is due to the fact the cyclopropyl derivatives
used as starting material are "trans". It is contemplated that the
cis configuration starting material or the individual
diastereoisomers could be used as starting material, all of which
are either commercially or synthetically available. Thus, the
invention relates to compounds of Formula (I) and those of the
examples that have specific stereochemical configurations around
the cyclopropyl ring e.g., trans ((1R, 2S) and/or (1S, 2R)) and cis
((1R, 2R) and/or (1S, 2S)). A preferred stereochemical
configuration around the cyclopropyl ring is trans.
[0457] The compounds of the examples can also be synthesized or
provided in a salt form. The skilled artisan is aware and capable
of making salt forms and/or converting salt forms of the compounds
of the invention, e.g., compounds of Formula (I) and those of the
Examples. In some cases the compounds of Formula (I) and the
Examples can be more stable as salt forms as compared to free
base.
[0458] In reference to the synthetic schemes described herein the
following intermediates (and analogous intermediates or derivatives
thereof can be made using the following procedures.
Intermediate A: (E)-ethyl 3-(6-bromopyridin-3-yl)acrylate
##STR00007##
[0460] Triethyl phosphonoacetate (26.6 g, 118.8 mmol) was added
slowly dropwise to a mixture of Potassium-tert-butoxide (14.5 g,
129.6 mmol) in dry THF (200 mL) at -5.degree. C., stirred for 20
min and then a solution of 6-bromopyridine-3-carboxaldehyde (20 g,
108 mmol) in dry THF (100 mL) was added slowly dropwise at
-5.degree. C. and stirred for 30 min. After completion, the
reaction mixture was poured into ice water (350 mL) and extracted
with EtOAc (2.times.300 mL). The combined organic extracts were
washed with saturated NaHCO.sub.3 solution (250 mL), water (250 mL)
and brine (250 mL) and dried over anhydrous Na.sub.2SO.sub.4,
filtered and evaporated to get (E)-ethyl 3-(6-bromopyridin-3-yl)
acrylate (20 g, 72.9%) as brown color liquid. This is carried to
next step without further purification.
Intermediate B:
(Trans)-ethyl-2-(6-bromopyridin-3-yl)cyclopropanecarboxylate
##STR00008##
[0462] Trimethyl sulfoxonium iodide (20.8 g, 94.7 mmol) was added
in small portions to a suspension of sodium hydride (4 g, 170.6
mmol) in dry DMSO (400 mL) at rt., stirred for 1 h until clear
solution was obtained. A solution of (E)-ethyl
3-(6-bromopyridin-3-yl) acrylate (Intermediate A, 20 g, 78.7 mmol)
in dry DMSO (20 mL) was added and stirred for 4 h. After
completion, the reaction mixture was poured into ice water (700
mL), extracted with EtOAc (2.times.350 mL). The combined organic
extracts were washed with water (250 mL), brine (250 mL) and dried
over anhydrous Na.sub.2SO.sub.4, filtered and evaporated to give
(trans)-ethyl-2-(6-bromopyridin-3-yl)cyclopropanecarboxylate (10 g,
47%) as brown liquid.
Intermediate C:
(Trans)-2-(6-bromopyridin-3-yl)cyclopropanecarboxylic acid
hydrochloride
##STR00009##
[0464] NaOH 4N solution (60 mL) was added to a solution of
(trans)-ethyl-2-(6-bromopyridin-3-yl)cyclopropanecarboxylate
(Intermediate B, 10 g, 37.1 mmol) in methanol (100 mL) and the
reaction mixture was stirred at RT for 4 h. After completion, the
solvent was evaporated and the residue was diluted with ice water
(250 mL) and acidified with 4 N HCl solution, the aqueous layer was
extracted with EtOAc (2.times.350 mL). The combined organic
extracts were washed with water (250 mL), brine (250 mL) and dried
over anhydrous Na.sub.2SO.sub.4, filtered and evaporated to give
(trans)-2-(6-bromopyridin-3-yl)cyclopropanecarboxylic acid
hydrochloride (5 g, 55.8%) as a light brown color solid.
Intermediate D: (Trans)-2-(6-bromopyridin-3-yl)cyclopropanecarbonyl
azide
##STR00010##
[0466] Ethyl chloroformate (5.8 mL, 62 mmol) was added to a
solution of (trans)-2-(6-bromopyridin-3-yl)cyclopropanecarboxylic
acid hydrochloride (Intermediate C, 5 g, 20.7 mmol) and Et.sub.3N
(14.2 mL, 103.7 mmol) in Acetone (100 mL) at -5.degree. C., then
reaction mixture was stirred at -5.degree. C. for 1 h, then a
solution of NaN.sub.3 (2.7 g, 41.4 mmol) in water (10 mL) was added
and stirred for 30 mins at RT. After completion the solvent was
evaporated under vacuum. The crude residue was dissolved in ethyl
acetate (200 mL), washed with water (80 mL), brine (80 mL), dried
over anhydrous Na.sub.2SO.sub.4, filtered and evaporated to get
(trans)-2-(6-bromopyridin-3-yl)cyclopropanecarbonyl azide (2.5 g,
45.5%) as a brown color gummy liquid.
Intermediate E: tert-butyl
(trans)-2-(6-bromopyridin-3-yl)cyclopropylcarbamate
##STR00011##
[0468] A solution of
(trans)-2-(6-bromopyridin-3-yl)cyclopropanecarbonyl azide
(Intermediate D, 2.5 g, 9.36 mmol) in tert-butanol (80 mL) was
heated at 90.degree. C. for 16 h. After completion, the solvent was
evaporated under vacuum and the residue was taken in water (100 mL)
and extracted with EtOAc (2.times.100 mL). The combined organic
extracts were washed with water (100 mL), brine (100 mL) and dried
over anhydrous Na.sub.2SO.sub.4, filtered and evaporated. The crude
residue was purified by flash column chromatography (SiO.sub.2) by
eluting with EtOAc: Hexane (2:8) to get tert-butyl
(trans)-2-(6-bromopyridin-3-yl)cyclopropylcarbamate (1.1 g, 37.5%)
as a light yellow solid. .sup.1H-NMR (CDCl.sub.3) .delta. (ppm):
1.16 (q, 1H), 1.23 (quin, 1H), 1.45 (s, 9H), 2.01 (m, 1H), 2.69 (m,
1H), 4.88 (br, 1H), 7.36 (s, 2H), 8.20 (s, 1H).
Example 1
5-((trans)-2-aminocyclopropyl)-N-(3-chlorophenyl)pyridin-2-amine
hydrochloride
##STR00012##
[0469] Step 1
[0470] A solution of tert-butyl
(trans)-2-(6-bromopyridin-3-yl)cyclopropylcarbamate (Intermediate
E, 250 mg, 0.798 mmol), 3-chloroaniline (122 mg, 0.958 mmol),
Sodium tert-butoxide (115 mg, 1.198 mmol) in 1,4-dioxane (5 mL) was
degassed for 30 min, tris(dibenzylidene acetone)dipalladium (0) (36
mg, 0.039 mmol) and 4,5-Bis(diphenyl phosphino)-9,0-dimethyl
xanthene (138 mg, 0.39 mmol) was added and heated for 4 h at 80 OC.
After completion, the solvent was evaporated; the residue was
poured into ice cold water (10 mL) and extracted with EtOAc
(2.times.20 mL). The combined extracts were washed with water (10
mL), brine (10 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered
and evaporated. The crude residue was purified by flash
chromatography to give tert-butyl
(trans)-2-(6-(3-chlorophenylamino)pyridin-3-yl)cyclopropylcarbamate
(180 mg, 63%) as white solid.
Step 2
[0471] HCl in dioxane (2 ml) was added to a solution of tert-butyl
(trans)-2-(6-(3-chlorophenylamino)pyridin-3-yl)cyclopropyl
carbamate (180 mg, 0.501 mmol) in 1,4-dioxane (2 mL) at 0.degree.
C. and stirred at RT for 4 h. After completion, the solvent was
evaporated and the residue was triturated with diethyl ether (5 mL)
followed by n-pentane (5 mL) to give
5-((trans)-2-aminocyclopropyl)-N-(3-chlorophenyl)pyridin-2-amine
hydrochloride (120 mg, 81%) as off-white solid. .sup.1H-NMR (400
MHz, DMSO-d6) .delta.: 1.2 (br, 1H), 1.4 (br, 1H), 2.3 (br, 1H),
2.8 (br, 1H), 7.0 (br, 2H), 7.31 (t, 1H), 7.42 (d, 1H), 7.54 (br,
1H), 7.87 (s, 1H), 8.06 (s, 1H), 8.59 (br, 2H), 9.82 (br, 1H); MS
(M+H): 260.1
[0472] The following compounds can be synthesized following the
method described for example 1 using the corresponding commercial
available anilines.
Example 2
5-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)pyridin-2-amine
hydrochloride
##STR00013##
[0474] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.2 (q, 1H), 1.4
(quin, 1H), 2.3 (m, 1H), 2.8 (m, 1H), 6.95 (br, 1H), 7.37 (d, 2H),
7.55 (br, 1H), 7.61 (d, 2H), 8.02 (s, 1H), 8.55 (br, 2H), 9.78 (br,
1H);
[0475] MS (M+H): 260.1
Example 3
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)phenyl)pyridin-2-amin-
e hydrochloride
##STR00014##
[0477] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.2 (q, 1H), 1.4
(quin, 1H), 2.3 (m, 1H), 2.8 (m, 1H), 6.93 (br, 1H), 7.47 (br, 1H),
7.59 (d, 2H), 7.85 (d, 2H), 8.11 (s, 1H), 8.51 (br, 2H), 9.71 (br,
1H);
[0478] MS (M+H): 294.1
Example 4
5-((trans)-2-aminocyclopropyl)-N-(3-methoxyphenyl)pyridin-2-amine
hydrochloride
##STR00015##
[0480] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.23 (q, 1H), 1.42
(quin, 1H), 2.35 (br, 1H), 2.82 (br, 1H), 3.76 (s, 3H), 6.73 (br,
1H), 7.0-7.2 (m, 3H), 7.30 (t, 1H), 7.70 (br, 1H), 7.99 (s, 1H),
8.66 (br, 3H), 10.25 (br, 1H); MS (M+H): 256.1
Example 5
5-((trans)-2-aminocyclopropyl)-N-(4-methoxyphenyl)pyridin-2-amine
hydrochloride
##STR00016##
[0482] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.22 (q, 1H), 1.42
(quin, H), 2.36 (m, 1H), 2.80 (m, 1H), 3.78 (s, 3H), 7.01 (d, 3H),
7.34 (d, 2H), 7.75 (d, 1H), 7.88 (s, 1H), 8.66 (br, 2H), 10.22 (br,
1H); MS (M+H): 256.2
Example 6
5-((trans)-2-aminocyclopropyl)-N-p-tolylpyridin-2-amine
hydrochloride
##STR00017##
[0484] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.23 (q, 1H), 1.40
(quin, 1H), 2.30 (s, 3H), 2.33 (br, 1H), 2.80 (m, 1H), 7.00 (br,
1H), 7.20 (d, 2H), 7.35 (d, 2H), 7.67 (br, 1H), 7.93 (s, 1H), 8.58
(br, 3H), 10.00 (br, 1H); MS (M+H): 240.2
Example 7
5-((trans)-2-aminocyclopropyl)-N-m-tolylpyridin-2-amine
hydrochloride
##STR00018##
[0486] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.23 (q, 1H), 1.42
(quin, 1H), 2.31 (s, 3H), 2.38 (br, 1H), 2.82 (m, 1H), 6.95 (br,
1H), 7.10 (br, 1H), 7.28 (m, 3H), 7.70 (br, 1H), 7.97 (s, 1H), 8.61
(br, 3H), 10.05 (br, 1H); MS (M+H): 240.2
Example 8
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile
hydrochloride
##STR00019##
[0488] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.19 (q, 1H), 1.38
(quin, 1H), 2.32 (m, 1H), 2.79 (m, 1H), 6.95 (t, 1H), 7.47 (br,
1H), 7.67 (d, 2H), 7.85 (d, 2H), 8.13 (s, 1H), 8.54 (br, 3H), 9.85
(br, 1H); MS (M+H): 251.2
Example 9
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzonitrile
hydrochloride
##STR00020##
[0490] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.22 (q, 1H), 1.38
(quin, 1H), 2.30 (br, 1H), 2.80 (br, 1H), 6.91 (br, 1H), 7.32 (s,
1H), 7.47 (m, 2H), 7.78 (d, 1H), 8.10 (s, 1H), 8.28 (s, 1H), 8.50
(br, 3H), 9.75 (br, 1H); MS (M+H): 251.2
Example 10
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide
hydrochloride
##STR00021##
[0492] .sup.1H-NMR (400 MHz, DMSO D6) .delta.: 1.29 (q, 1H), 1.46
(quin, 1H), 2.42 (m, 1H), 2.89 (m, 1H), 7.45 (d, 1H), 7.54 (t, 1H),
7.70 (d, 1H), 7.82 (d, 1H), 7.91 (br, 1H), 8.10 (d, 1H), 8.32 (s,
1H), 8.59 (br, 3H), 11.05 (br, 1H); MS (M+H): 269.2
Example 11
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)benzamide
hydrochloride
##STR00022##
[0494] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.32 (q, 1H), 1.48
(quin, 1H), 2.44 (br, 1H), 2.91 (m, 1H), 6.74 (m, 2H), 7.90 (m,
2H), 8.09 (m, 1H), 8.10 (d, 1H), 8.32 (s, 1H), 8.60 (br, 3H), 11.21
(br, 1H); MS (M+H): 269.2
Example 12
5-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)pyridin-2-amine
hydrochloride
##STR00023##
[0495] Step 1
[0496] A solution of tert-butyl
(trans)-2-(6-bromopyridin-3-yl)cyclopropylcarbamate (Intermediate
E, 350 mg, 1.118 mmol), 3-chlorobenzylamine (237 mg, 1.677 mmol),
Sodium tert-butoxide (161 mg, 1.677 mmol) in 1,4-dioxane (7 mL) was
degassed for 30 min, tris(dibenzylidene acetone)dipalladium (0) (51
mg, 0.055 mmol), 4,5-Bis(diphenyl phosphino)-9,0-dimethyl xanthene
(193 mg, 0.335 mmol) was added and heated for 4 h at 80.degree. C.
After completion, the solvent was removed, the residue was poured
into ice cold water (10 mL) and extracted with EtOAc (2.times.20
mL). The combined extracts were washed with water (10 mL), brine
(10 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered and
evaporated. The crude residue was purified by flash chromatography
to give tert-butyl
(trans)-2-(6-(3-chlorobenzylamino)pyridin-3-yl)cyclopropyl
carbamate (100 mg, yield: 24%) as white solid.
Step 2
[0497] HCl in Dioxane (1 ml) was added to a solution of tert-butyl
(trans)-2-(6-(3-chlorobenzylamino)pyridin-3-yl)cyclopropyl
carbamate (100 mg, 0.268 mmol) in 1,4-dioxane (1 mL) at 0.degree.
C., stirred at RT for 4 h. After completion, the solvent was
removed and the residue was triturated with diethyl ether (5 mL)
followed by n-pentane (5 mL) to give
5-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)pyridin-2-amine
hydrochloride (60 mg, yield: 72.2%) as off-white solid. .sup.1H-NMR
(400 MHz, DMSO-d6) .delta.: 1.21 (q, 1H); 1.38 (quin, 1H), 2.32 (m,
1H), 2.81 (m, 1H), 4.67 (s, 2H), 7.04 (d, 1H), 7.40 (m, 3H), 7.49
(s, 1H), 7.74 (d, 1H), 7.86 (s, 1H), 8.57 (br, 3H), 9.06 (br, 1H).
Mass (M+H): 274.2
[0498] The following compounds can be synthesized following the
method described for example 12 using the corresponding commercial
available amines.
Example 13
5-((trans)-2-aminocyclopropyl)-N-(4-chlorobenzyl)pyridin-2-amine
hydrochloride
##STR00024##
[0500] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.26 (q, 1H); 1.37
(quin, 1H), 2.32 (m, 1H), 2.81 (m, 1H), 4.60 (s, 2H), 7.05 (d, 1H),
7.43 (q, 4H), 7.74 (d, 1H), 7.82 (s, 1H), 8.62 (br, 3H), 9.16 (br,
1H). Mass (M+H): 274.2
Example 14
5-((trans)-2-aminocyclopropyl)-N-(3-(trifluoromethyl)benzyl)pyridin-2-amin-
e hydrochloride
##STR00025##
[0502] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.:1.22 (q, 1H); 1.39
(quin, 1H), 2.33 (m, 1H), 2.81 (m, 1H), 4.76 (s, 2H), 7.07 (d, 1H),
7.6-7.78 (m, 4H), 7.80 (s, 1H), 7.86 (s, 1H), 8.58 (br, 3H), 9.06
(br, 1H). Mass (M+H): 308.2
Example 15
5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)benzyl)pyridin-2-amin-
e hydrochloride
##STR00026##
[0504] .sup.1H-NMR (400 MHz, CD3OD) .delta.: 1.40 (q, 1H); 1.45
(quin, 1H), 2.39 (m, 1H), 2.92 (m, 1H), 4.71 (s, 2H), 7.09 (d, 1H),
7.60 (d, 2H), 7.69 (d, 2H), 7.80 (s, 1H), 7.83 (d, 1H). Mass (M+H):
308.2
Example 16
5-((trans)-2-aminocyclopropyl)-N-(3-methylbenzyl)pyridin-2-amine
hydrochloride
##STR00027##
[0506] .sup.1H-NMR (400 MHz, CD3OD) .delta.: 1.38 (q, 1H); 1.45
(quin, 1H), 2.34 (s, 3H), 2.38 (m, 1H), 2.91 (m, 1H), 4.54 (s, 2H),
7.07 (d, 1H), 7.16 (d, 2H), 7.21 (s, 1H), 7.27 (m, 1H), 7.76 (s,
1H), 7.81 (d, 1H). Mass (M+H): 254.2
Example 17
5-((trans)-2-aminocyclopropyl)-N-(4-methylbenzyl)pyridin-2-amine
hydrochloride
##STR00028##
[0508] .sup.1H-NMR (400 MHz, CD3OD) .delta.: 1.38 (q, 1H); 1.43
(quin, 1H), 2.33 (s, 3H), 2.38 (m, 1H), 2.91 (m, 1H), 4.53 (s, 2H),
7.06 (d, 1H), 7.20 (d, 2H), 7.26 (d, 2H), 7.76 (s, 1H), 7.78 (d,
1H). Mass (M+H): 254.2
Example 18
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzonitrile
hydrochloride
##STR00029##
[0510] .sup.1H-NMR (400 MHz, D.sub.2O) .delta.: 1.41 (q, 1H); 1.53
(quin, 1H), 2.47 (m, 1H), 2.96 (m, 1H), 4.74 (s, 2H), 7.06 (d, 1H),
7.63 (t, 1H), 7.75 (s, 2H), 7.78-7.85 (m, 3H). Mass (M+H):
265.2
Example 19
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzonitrile
hydrochloride
##STR00030##
[0512] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.18 (q, 1H); 1.31
(quin, 1H), 2.24 (m, 1H), 2.78 (m, 1H), 4.68 (s, 2H), 6.85 (br,
1H), 7.54 (d, 3H), 7.82 (d, 3H), 8.35 (s, 3H). Mass (M+H):
265.2
Example 20
5-((trans)-2-aminocyclopropyl)-N-(3-methoxybenzyl)pyridin-2-amine
hydrochloride
##STR00031##
[0514] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.22 (q, 1H); 1.39
(quin, 1H), 2.33 (m, 1H), 2.81 (m, 1H), 3.74 (s, 3H), 4.61 (s, 2H),
6.88 (d, 1H), 6.95 (d, 1H), 7.01 (s, 1H), 7.06 (m, 1H), 7.31 (t,
1H), 7.76 (d, 1H), 7.86 (s, 1H), 8.58 (br, 3H), 9.12 (br, 1H). Mass
(M+H): 270.2
Example 21
5-((trans)-2-aminocyclopropyl)-N-(4-methoxybenzyl)pyridin-2-amine
hydrochloride
##STR00032##
[0516] .sup.1H-NMR (400 MHz, DMSO-d6) .delta.: 1.22 (q, 1H); 1.38
(quin, 1H), 2.32 (m, 1H), 2.80 (m, 1H), 3.74 (s, 3H), 4.55 (s, 2H),
6.93 (d, 2H), 7.03 (s, 1H), 7.06 (m, 1H), 7.33 (d, 2H), 7.73 (d,
1H), 7.85 (s, 1H), 8.59 (s, 3H), 9.02 (br, 1H). Mass (M+H): 270.2
The following compounds can be synthesized following the method
described in Scheme 1.
Example 22
4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol
hydrochloride
##STR00033##
[0517] Example 23
3-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzamide
hydrochloride
##STR00034##
[0518] Example 24
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)benzamide
hydrochloride
##STR00035##
[0519] Example 25
4-((5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)methyl)phenol
hydrochloride
##STR00036##
[0520] Example 26
5-((trans)-2-aminocyclopropyl)-N-(3-ethynylphenyl)pyridin-2-amine
(or a hydrochloride salt thereof)
##STR00037##
[0521] Example 27
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indol-7-amine (or
a hydrochloride salt thereof)
##STR00038##
[0522] Example 28
N-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)-1H-indazol-7-amine
(or a hydrochloride salt thereof)
##STR00039##
[0523] Example 29
3-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino)phenol (or a
hydrochloride salt thereof)
##STR00040##
[0524] Example 30
4-((trans)-2-aminocyclopropyl)-N-(4-methylbenzyl)aniline
hydrochloride
##STR00041##
[0525] Example 31
4-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)benzyl)amine
hydrochloride
##STR00042##
[0526] Example 32
4-((trans)-2-aminocyclopropyl)-N-(3-chlorobenzyl)aniline
hydrochloride
##STR00043##
[0527] Example 33
3-(((4-((trans)-2-aminocyclopropyl)phenyl)amino)methyl)benzonitrile
hydrochloride
##STR00044##
[0528] Example 34
4-((trans)-2-aminocyclopropyl)-N-(p-tolyl)aniline hydrochloride
##STR00045##
[0529] Example 35
4-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)aniline
hydrochloride
##STR00046##
[0530] Example 36
3-((4-((trans)-2-aminocyclopropyl)phenyl)amino)benzonitrile
hydrochloride
##STR00047##
[0531] Example 37
N-(4-((trans)-2-aminocyclopropyl)phenyl)-3-methoxyaniline
hydrochloride OCH.sub.3
##STR00048##
[0532] Example 38
3-((4-((trans)-2-aminocyclopropyl)phenyl)amino)benzamide
hydrochloride
##STR00049##
[0533] Example 39
Biological Assays--Inhibition of LSD1
[0534] The compounds of the invention can be tested for their
ability to inhibit LSD1. The ability of the compounds of the
invention to inhibit LSD1 can be tested as follows. Human
recombinant LSD1 protein was purchased from BPS Bioscience Inc. In
order to monitor LSD1 enzymatic activity and/or its inhibition rate
by our inhibitor(s) of interest, di-methylated H3-K4 peptide
(Millipore) was chosen as a substrate. The demethylase activity was
estimated, under aerobic conditions, by measuring the release of
H.sub.2O.sub.2 produced during the catalytic process, using the
Amplex.RTM. Red peroxide/peroxidase-coupled assay kit
(Invitrogen).
[0535] Briefly, a fixed amount of LSD1 was incubated on ice for 15
minutes, in the absence and/or in the presence of various
concentrations of inhibitor (e.g., from 0 to 75 .mu.M, depending on
the inhibitor strength). Tranylcypromine (Biomol International) was
used as a control for inhibition. Within the experiment, each
concentration of inhibitor was tested in triplicate. After leaving
the enzyme interacting with the inhibitor, 12.5 .mu.M of
di-methylated H3-K4 peptide was added to each reaction and the
experiment was left for 1 hour at 37.degree. C. in the dark. The
enzymatic reactions were set up in a 50 mM sodium phosphate, pH 7.4
buffer. At the end of the incubation, Amplex.RTM. Red reagent and
horseradish peroxidase (HPR) solution were added to the reaction
according to the recommendations provided by the supplier
(Invitrogen), and left to incubate for 30 extra minutes at room
temperature in the dark. A 1 .mu.M H.sub.2O.sub.2 solution was used
as a control of the kit efficiency. The conversion of the
Amplex.RTM. Red reagent to resorufin due to the presence of
H.sub.2O.sub.2 in the assay, was monitored by fluorescence
(excitation at 540 nm, emission at 590 nm) using a microplate
reader (Infinite 200, Tecan). Arbitrary units were used to measure
level of H.sub.2O.sub.2 produced in the absence and/or in the
presence of inhibitor.
[0536] The maximum demethylase activity of LSD1 was obtained in the
absence of inhibitor and corrected for background fluorescence in
the absence of LSD1. The Ki (IC50) of each inhibitor was estimated
at half of the maximum activity.
[0537] The results presented in Table 1 below show the results of
the LSD1 inhibition studies for a number of the Example compounds.
Parnate (tranylcypromine; i.e., 2-trans phenylcyclopropylamine) was
found to have a Ki of from about 15 to 35 micromolar depending on
the enzyme preparation. The studies show that the compounds of the
invention have unexpectedly potent LSD1 inhibition.
Example 40
Biological Assays--Monoamine Oxidase Assays for Determining the
Selectivity of the Compounds of the Invention for LSD1
[0538] Human recombinant monoamine oxidase proteins MAO-A and MAO-B
were purchased from Sigma Aldrich. MAOs catalyze the oxidative
deamination of primary, secondary and tertiary amines. In order to
monitor MAO enzymatic activities and/or their inhibition rate by
inhibitor(s) of interest, a fluorescence-based
(inhibitor)-screening assay was set up.
3-(2-Aminophenyl)-3-oxopropanamine (kynuramine dihydrobromide,
Sigma Aldrich), a non fluorescent compound was chosen as a
substrate. Kynuramine is a non-specific substrate for both MAO-A
and MAO-B activities. While undergoing oxidative deamination by MAO
activities, kynuramine is converted into 4-hydroxyquinoline (4-HQ),
a resulting fluorescent product.
[0539] The monoamine oxidase activity was estimated by measuring
the conversion of kynuramine into 4-hydroxyquinoline. Assays were
conducted in 96-well black plates with clear bottom (Corning) in a
final volume of 100 .mu.L. The assay buffer was 100 mM HEPES, pH
7.5. Each experiment was performed in triplicate within the same
experiment.
[0540] Briefly, a fixed amount of MAO (0.25 .mu.g for MAO-A and 0.5
.mu.g for MAO-B) was incubated on ice for 15 minutes in the
reaction buffer, in the absence and/or in the presence of various
concentrations of inhibitor (e.g., from 0 to 50 .mu.M, depending on
the inhibitor strength). Tranylcypromine (Biomol International) was
used as a control for inhibition.
[0541] After leaving the enzyme(s) interacting with the inhibitor,
60 to 90 .mu.M of kynuramine was added to each reaction for MAO-B
and MAO-A assay respectively, and the reaction was left for 1 hour
at 37.degree. C. in the dark. The oxidative deamination of the
substrate was stopped by adding 50 .mu.L (v/v) of NaOH 2N. The
conversion of kynuramine to 4-hydroxyquinoline, was monitored by
fluorescence (excitation at 320 nm, emission at 360 nm) using a
microplate reader (Infinite 200, Tecan). Arbitrary units were used
to measure levels of fluorescence produced in the absence and/or in
the presence of inhibitor.
[0542] The maximum of oxidative deamination activity was obtained
by measuring the amount of 4-hydroxyquinoline formed from
kynuramine deamination in the absence of inhibitor and corrected
for background fluorescence in the absence of MAO enzymes. The Ki
(IC50) of each inhibitor was determined at Vmax/2.
TABLE-US-00001 TABLE 1 Summary of Data from MAO-A, MAO-B, and LSD1
Inhibition Studies (Examples 39 and 41) Example MAO-A MAO-B LSD1
No. (Ki) (Ki) (Ki) 1 I III II 2 I III II 3 I II II 4 I I II 5 I II
II 6 I I II 7 I II II 9 I II II 10 I I II 12 I I II 15 I I II 16 I
I II 17 I I II 18 I I II
[0543] The ranges for the Ki value reported in Table 1 are for
MAO-A, MAO-B and LSD1: I=between 1 .mu.M and 40 .mu.M; II=between
0.1 .mu.M and 1 .mu.M; III=between 0.001 .mu.M and 0.1 .mu.M.
[0544] Generally compounds of the Examples were found to have
particularly low Ki (IC50) values for MAO-B and LSD1, as compared
to MAO-A. For some of the compounds of the Examples, Ki (IC50)
values for LSD1 were lower than 0.5 .mu.M.
[0545] Some compounds of the Examples have been tested for
antiproliferative/cytotoxic activity and been found to have
activity in the micromolar to low micromolar range against cancer
cell lines including HCT-116.
[0546] Previous reports of LSD1 have found that it is involved in
cell proliferation and growth.
[0547] Some studies have implicated LSD1 as a therapeutic target
for cancer. Huang et al. (2007) PNAS 104:8023-8028 found that
polyamine inhibitors of LSD1 modestly cause the reexpression of
genes aberrantly silenced in cancer cells and particularly
colorectal cancer (Huang el al. Clin Cancer Res. (2009) Dec. 1; 15
(23):7217-28. Epub 2009 Nov. 24. PMID: 19934284). Scoumanne et al.
((2007) J. Biol. Chem. May 25; 282 (21):15471-5) found that
deficiency in LSD1 leads to a partial cell cycle arrest in G2/M and
sensitizes cells to growth suppression induced by DNA damage. Kahl
et al. ((2006) Cancer Res. 66(23):11341-7) found that LSD1
expression is correlated with prostate cancer aggressiveness.
Metzger et al. reported that LSD1 modulation by siRNA and pargyline
regulates androgen receptor (AR) and may have therapeutic potential
in cancers where AR plays a role, like prostate, testis, and brain
cancers. Lee et al. ((2006) Chem. Biol. 13:563-567) reported that
tranylcypromine derepresses Egr-1 gene expression in some cancer
lines. A body of evidence is accumulating that Egr-1 is a tumor
suppressor gene in many contexts (see e.g., Calogero et al. (2004)
Cancer Cell International 4:1 exogenous expression of EGR-1
resulted in growth arrest and eventual cell death in primary cancer
cell lines; Lucerna et al. (2006) Cancer Research 66, 6708-6713
show that sustained expression of Egr-1 causes antiangiogenic
effects and inhibits tumor growth in some models; Ferraro et al.
((2005) J. Clin. Oncol. March 20; 23 (9):1921-6) reported that
Egr-1 is downregulated in lung cancer patients with a higher risk
of recurrence and may be more resistant to therapy. Thus,
increasing Egr-1 expression via inhibition of LSD1 is a therapeutic
approach for some cancers. Recent studies have also implicated LSD1
in brain cancer (Schulte et al. (2009) Cancer Res. March 1; 69
(5):2065-71). Other studies have implicated LSD1 in breast cancer
(Lims et al. Carcinogenesis. 2009 Dec. 30. [Epub ahead of print]
PMID: 20042638).
[0548] Thus, a body of evidence has implicated LSD1 in a number of
cancers, which suggests that LSD1 is a therapeutic target for
cancer. The instant inventors have discovered a class of LSD1
inhibitors that can be used to treat diseases where LSD1 is
implicated as a therapeutic target like cancer. Accordingly, the
compounds of the invention can be used to treat such diseases.
[0549] Recent studies have also implicated LSD1 in viral infection
and reactivation. In particular it was shown that pharmacological
inhibitors of LSD1 like parnate and siRNA knock down of LSD1 caused
reduced viral infectivity and reduced reactivation after latency
(Liang et al. (2009) Nat. Med. 15:1312-1317). Therefore it is
believed that the compounds of the invention can be used for
treating or preventing viral infection. Furthermore, it is believed
that the compounds of the invention can treat or prevent viral
reactivation after latency.
[0550] Thus, without being bound by theory, the inventors have
identified a new class of cyclylcyclopropylamine containing LSD1
inhibitors with unexpected potency for LSD1, a biologically
relevant target in oncology and other diseases.
[0551] All publications and patent applications mentioned in the
specification are indicative of the level of those skilled in the
art to which this invention pertains. All publications and patent
applications are herein incorporated by reference to the same
extent as if each individual publication or patent application was
specifically and individually indicated to be incorporated by
reference. The mere mentioning of the publications and patent
applications does not necessarily constitute an admission that they
are prior art to the instant application.
[0552] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, it will be obvious that certain changes and
modifications may be practiced within the scope of the appended
claims.
* * * * *